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Carbapenemase-producing Enterobacteriaceae (CPE): include all Enterobacteriaceae that are 
resistant to the carbapenems via the production of carbapenemases only.  
 
Carbapenem-resistant Enterobacteriaceae (CRE): include all Enterobacteriaceae that are 
resistant to the carbapenems via several mechanisms of resistance such as extended-spectrum β-
lactamase (ESBL) production (including carbapenemases), ESBL-AmpC combination, outer- 
membrane impermeability and efflux pumps. 
 
Dehydropeptidase-1 (DHP-1): Dehydropeptidase is an enzyme found in the kidney and is 
responsible for degrading the antibiotic imipenem. 
 
recA: a protein that is responsible for the repair and maintenance of DNA.  
 
Spheroplasts: a cell from which the cell wall has been almost completely removed, as by the 
action of an antimicrobial agent. Once the microbial cell wall is digested, membrane tension 
causes the cell to acquire a characteristic spherical shape. 
 
Tubular brush-border: the proximal tubule which is the part of the duct system of the nephron of 




Zwitterionic molecular charge: a neutral molecule with a positive and a negative electrical 


























Carbapenem resistance has been linked to many mechanisms including inactivating enzyme 
production, outer membrane impermeability and efflux.  In recent literature, carbapenemases 
have been reported as the primary cause for the increase in carbapenem-resistance in Gram- 
negative Enterobacteriaceae. These enzymes are β-lactamases and have the ability to hydrolyse 
almost all β-lactam antibiotics including carbapenems, which are used for the treatment of severe 
nosocomial infections. Since 2011, individual cases and outbreaks with carbapenemase-
producing Enterobacteriaceae (CPE) have been reported in several hospitals in South Africa. 
Carbapenem resistance limits antibiotic choices, especially in the hospital setting, and may result 
in increased morbidity and mortality rates. As carbapenem resistance disseminates globally, 
more reports surface describing outbreaks affecting primarily more vulnerable hospital 
populations like neonates. Infection prevention and control (IPC) measures coupled with 
antibiotic stewardship policies have become paramount in the care of hospitalised patients and 
are crucial to addressing the problem of ever decreasing antibiotic choices. The rapid detection 
of carbapenem-resistant Enterobacteriaceae (CRE) will greatly assist in the application of IPC 












Carbapenemases are the primary cause for the increase in carbapenem resistance in Gram- 
negative Enterobacteriaceae. These enzymes are β-lactamases and have the ability to hydrolyse 
almost all β-lactam antibiotics thereby inactivating carbapenems that are used for the treatment 
of severe nosocomial infections. Multiple CPE outbreaks and epidemics have been reported in 
several hospitals in South Africa since the year 2011. This resulted in an increase in the 
morbidity and mortality rates and are slowly disseminating globally among more vulnerable 
individuals including neonates. Therefore, the aim of the study was to determine appropriate 
techniques for the rapid detection of carbapenem-resistant Enterobacteriaceae (CRE) (including 
CPE) isolated from neonates from King Edward VIII Hospital as well as to determine the 
molecular mechanisms conferring carbapenemase production in this subset of isolates. A total of 
94 Klebsiella pneumoniae and 41 Enterobacter cloacae samples were isolated in this study. 
Among these species 10 % (9/ 94) and 39 % (16/ 41) of K. pneumoniae and E .cloacae 
respectively, were resistant to the carbapenems based on the Kirby-Bauer susceptibility tests, 
microbroth-dilution and E-tests. However, screening for carbapenemase production using 
chromogenic agar (Brilliance™ CRE agar and ChromID® CARBA agar), Modified Hodge test 
and amoxycillin-clavulanate double disc synergy test did not correlate with these resistance 
patterns and exhibited false positive results possibly due to the presence of extended spectrum 
beta-lactamase (ESBL) production by these organisms. Due to such discrepancies in the 
phenotypic results, further detection for the presence of carbapenemases was performed using 
multiplex real-time PCR assays. This revealed the presence of the blaOXA-48 gene in only 1 K. 
pneumoniae isolate. Further molecular characterisation will be required to determine if alternate 
mechanisms of resistance are present in the resistant isolates detected in this study.     





The family of Enterobacteriaceae comprises  Gram-negative, rod shaped bacteria, some of 
which are inclusive of Escherichia spp., Enterobacter spp., Klebsiella spp., Proteus spp., 
Citrobacter spp., Serratia spp., Salmonella spp., Shigella spp., Yersinia spp., Morganella 
spp., and Providencia spp. (Martin et al., 2013). Some of these potentially pathogenic 
organisms inhabit the intestinal tract and are common sources of hospital-acquired infections 
(Nordmann et al., 2012). These organisms may cause gastrointestinal and extraintestinal 
infections such as urinary tract infections, respiratory tract infections, skin and soft tissue 
infections and infections of the central nervous system  (Kurakawa et al., 2013; Nordmann et 
al., 2012; Paterson, 2006).  
 
 
A number of these pathogens have become prevalent in hospitals in the form Multi-Drug 
resistant (MDR) strains (Kurakawa et al., 2013). These MDR strains occur more frequently 
among patients with severe illnesses, including those in Intensive Care Units (ICUs) 
(Kurakawa et al., 2013). Neonates are an especially vulnerable group due to their immature 
immune systems (Vergnano and Heath, 2013; Zaidi et al., 2011). The main route of 
transmission of Enterobacteriaceae in hospitals is via direct patient-to-hospital personnel and 
patient-to-patient contact. Indirect contact may also occur due to contamination of inanimate 
objects such as equipment or medication vials. An alternate means of transmission may be a 
result of ingestion of contaminated food and water at the hospital (Nordmann et al., 2012). 
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Over the past few years, the resistance of Enterobacteriaceae to common antimicrobial 
agents has increased significantly (DiPersio and Dowzicky, 2007). These antimicrobial 
agents include tetracycline, β-lactams, fluoroquinolones, polymyxins, aminoglycosides and 
co-trimoxazole, third- and fourth-generation cephalosporins (Bonelli et al., 2014; DiPersio 
and Dowzicky, 2007; Tang et al., 2014). The increase in the prevalence of ESBL producing 
organisms has led to an increased use of carbapenems.  This has resulted in an increase in the 
antibiotic pressure on carbapenems which lends to the activation of bacterial resistance genes 
against these drugs (El-Herte et al., 2012). Carbapenem resistance may result from the 
production of carbapenemases, outer membrane impermeability, efflux pumps, or a 
combination of these.  
 
 
Carbapenemase-producing Enterobacteriaceae (CPE) is on the increase and have been 
reported globally (El-Herte et al., 2012). In developing countries like South Africa, CPE and 
ESBL-producing Enterobacteriaceae are widespread (Martin et al., 2013). Therefore, 
clinicians are faced with the decision to treat seriously ill patients with toxic empiric therapies 
such as colistin and tigercycline (Martin et al., 2013).  
 
 
Carbapenemase production by Enterobacteriaceae is viewed as the most clinically significant 
resistance mechanism from a public health perspective (Martin et al., 2013). The genes 
responsible for CPE are primarily plasmid-encoded and associated with various mobile 
genetic elements (Gazin  et al., 2012; Patel et al.,  2009). These are able to accumulate 
resistance genes to a number of different antibiotics and are easily transferrable between 
bacterial species (Bush et al., 2013; DiPersio and Dowzicky, 2007). The implementation of 
- 3 - 
 
strict infection control measures in order to prevent the spread of carbapenemase encoding 
genes to unrelated clones or to other bacterial species is paramount. It is therefore essential 
that patients colonised or infected with these organisms are rapidly identified and cohort 
nursed with strict contact precautions. The reliable detection of carbapenem-resistant 
organisms  is also essential in outbreak detection and for the institution of appropriate 
treatment options (Stuart and Leverstein-Van Hall, 2010; Kaase et al., 2012). 
 
 
Many phenotypic tests can be used as indicators of resistance determinants, thereafter 
molecular techniques may be perform for confirmation of these resistance determinants. It is 
debatable as to which test is most effective (Stuart and Leverstein-Van Hall, 2010; Nordmann 
et al., 2009; Thomson, 2010). However, carbapenemase production is linked to the 
transference of plasmid-mediated genes encoding the carbapenemases within and between 
species (Bush et al., 2013; DiPersio and Dowzicky, 2007). These enzymes are normally 
produced in combination with several other β-lactamases, hence making it  difficult to 
identify carbapenemases using simple phenotypic methods (Bush et al., 2013) 
 
 
The aim of this study was to screen for CRE amongst neonates at King Edward VIII Hospital, 
Durban, South Africa by means of susceptibility testing and minimum inhibitory 
concentration (MIC) determination. Additionally screening for CPE using previously 
described phenotypic tests was evaluated and correlated with multiplex real-time polymerase 
chain reaction (PCR) for the production of carbapenemases. 
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The objectives of this study were: 
 To isolate Enterobacteriaceae from rectal swabs. 
 To determine the carbapenem susceptibility based on the Brilliance™ CRE Agar and 
Kirby-Bauer tests. 
 To compare the carbapenem MICs based on the microbroth dilution, E-Test and 
VITEK® 2 Automated System. 
 To ascertain carbapenemase production based on the ChromID® CARBA agar, 
Modified Hodge Test and Amoxycillin-Clavulanate Double Disc Synergy Test. 
 To link the results of the phenotypic tests with the results from the multiplex real-time 





















2.1. INFECTIONS IN NEONATES 
 
The World Health Organisation estimated that about 41% (3.6 million) of under 5 year old 
deaths occur during the neonatal period (Hoque et al., 2011). Most of these deaths occur in 
developing countries and approximately 1 million deaths are attributed to infections such as 
neonatal sepsis, meningitis and pneumonia (Zaidi et al., 2011). In South Africa, the most 
common reasons for neonatal deaths are birth asphyxia, prematurity, neonatal bacterial 
infection and congenital abnormality (Pattinson, 2007). Neonates are highly susceptible to 
bacterial infections, and an immature immune system may lead to the rapid progression of 
disease. In addition, there may be a delay in recognition and treatment of such infections due 
to poor recognition of symptoms and constraints of healthcare resources (Zaidi et al., 2011).  
 
 
2.1.1 Acquisition of Neonatal Infections 
 
Neonates are immunocompromised due to their thin skin and mucous membranes (which are 
weak barriers against infections) and an immature immune system with respect to specific 
and innate immunity (Vergnano and Heath, 2013). Infections in neonates may occur as a 
result of vertical transmission in utero, acquisition during the peripartum period or 
nosocomial infections following delivery.  
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In 1998, in South Africa, a rate of 21 per 1000 live births occurred. According to the 
Statistics South Africa, in 2009, the neonatal mortality rate decreased to 14 per 1000 live 
births, with a target decrease of 7 per 1000 predicted for the year 2015 (Lloyd and de Witt, 
2013; Velaphi and Rhoda, 2012). The rate of mortality in under-fives has increased as a result 




The TORCH group (Toxoplasma gondii; Others such as Parvovirus B19, Varicella-Zoster 
virus infection, Treponema pallidum infection, Hepatitis B; Rubella virus, Cytomegalovirus 
infection and Herpes Simplex virus infection) comprise organisms that predominantly cause 
congenital infection during pregnancy (van der Weiden et al., 2011). The gestational age of 
the fetus influences the severity of such infections. 
 
 
Early onset infections are referred to as infections that occur 2 to 3 days after birth, and are 
caused by the transmission of pathogens from the birth canal during or before birth (Fleming 
et al., 2012). The incidence of early onset infections vary from <1 to 10 per 1000 live births 
(Vergnano and Heath, 2013). The most common pathogens leading to early onset infections 
in developed countries are Group B streptococci and E. coli, followed by S. aureus and 
Listeria monocytogenes (Capretti and Faldella, 2013).  
 
 
Late-onset infections in hospitalised neonates occur after 48 hours of birth and are primarily 
nosocomial (Fleming et al., 2012). The incidence of late-onset infection differs from 20 to 30 
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per 1000 neonatal admissions in western countries (Vergnano and Heath, 2013). These 




In developed countries the most common infections are caused by coagulase-negative 
staphylococci, followed by S. aureus, E. coli, Klebsiella spp., and other Enterobacteriaceae 
(Fleming et al., 2012; Vergnano et al., 2011). Gram-negative rods are a common cause of 
nosocomial infection in neonates in developing countries. K. pneumoniae has been shown to 
account for between  16-28% of blood culture positives in septic neonates (Zaidi et al., 2005).  
 
 
2.1.2 Factors influencing Neonatal Infections 
 
Environmental risk factors associated with the transmission of infections are significant and 
related to the seasonal changes in the frequency of neonatal hospital acquired infections. 
Warmer climates are normally associated with increased colonisation with Enterobacter spp. 
(Fryklund et al., 1993). An increase in the humidity in the nursery, propagates airborne 
dispersion of Acinetobacter spp. and is associated with bloodstream infections (Srivastava 
and Shetty, 2007). Hospitalisation results in the colonisation of skin and gastrointestinal tract 
with resistant organisms present in hospitals (Srivastava and Shetty, 2007). This in turn leads 
to bloodstream infections when there are abrasions on the skin or mucosa. 
 
 
- 8 - 
 
Nosocomial pathogens are known for causing common-source outbreaks since they flourish 
in multi-use containers of medication, liquid soap, antiseptics, and disinfectants, as well as 
inadequately disinfected or sterilised equipment (Zaidi et al., 2005). The primary source of 
such infection is the hands of health-care personnel.              
 
 
Vertically acquired pathogens have the ability to cause infection of the amniotic fluid and 
stillbirths. In South Africa, the pathogens associated with neonatal sepsis suggest that many 
neonatal infections may be primarily acquired from the environment. The organism 
responsible for such infections is the group B Streptococcus (Cutland et al., 2009). Other 
pathogens that contribute to an increase in the mortality rate in neonates in South Africa 
include E. coli, Klebsiella spp., and Candida spp. 
 
 
2.1.3. Infection, Prevention and Control 
 
Several strategies may be implemented to prevent the spread of nosocomial pathogens in 
neonatal nurseries, including entry restrictions, maintenance of a clean environment outside 
the unit, and the promotion and practice of hand hygiene. In order to prevent or reduce the 
multiplication of environmental organisms, regular cleaning, disinfection and sterilisation of 
equipment and instruments are necessary (Shaffer, 2013). The transmission of organisms 
between the neonates may be further prevented by: reducing overcrowding in incubators and 
open cribs (Shaffer, 2013), promoting the use of disposable items and non-re-usable items, 
and increasing the hospital personnel-to-patient ratio by adequate staffing (Uwaezuoke and 
Obu, 2013). Whilst these strategies prevent colonisation and subsequent infection in 
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neonates, it must be partnered with antibiotic stewardship policies and practice to restrict the 
emergence and spread of antibiotic resistant organisms. 
 
2.1.4. Multi-Drug Resistant Nosocomial Pathogens  
 
There has been an increase in the resistance amongst Gram-negative and Gram-positive 
pathogens that cause infections in hospitals. These pathogens are referred to as ‘ESKAPE’ 
pathogens and comprise Enterococcus faecium, Staphylococcus aureus, Klebsiella 
pneumoniae, Acinetobacter baumanii, Pseudomonas aeruginosa and Enterobacter spp. 
(Boucher et al., 2013). The alarming rates of MDR are driven by poor infection-control 
practices as well as selective pressure of incorrect and prolonged used of antimicrobials. This 
allows for the emergence and amplification of resistance within hospital nurseries. 
‘ESKAPE’ pathogens have become a common occurrence in the healthcare environment 
(Boucher et al., 2009). The development of resistance amongst this group of pathogens is 
related to antibiotic usage patterns (Boucher et al., 2009).  
 
 
K. pneumoniae is one of the most important neonatal pathogens that occur in developing 
countries. Klebsiella spp. can be observed in the normal gastrointestinal and vaginal flora. 
However, its detection in a MDR form in hospital-born babies suggests that highly 
contaminated environmental reservoirs serve as a source of infection (Newman, 2002). The 
prevalence of these pathogens amongst neonates is cause for concern since colonization 
appears to occur at rapid rates (Chandrashekar et al., 1997; Newman, 2002).  
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2.2. β-LACTAM ANTIBIOTICS 
 
2.2.1. Mechanisms of Action  
 
β-lactams comprise a variety of antibiotics that are differentiated on the basis of their 
chemical structure. They can be divided into four groups which include penicillins, 
cephalosporins, monobactams and carbapenems.  
 
 
The activity of β-lactam antibiotics against bacteria results in the inhibition of the synthesis 
of the Peptidoglycan layer (PGL) (Nordmann et al., 2012). The final transpeptidation step 
during PGL synthesis involves the transpeptidases known as peptidoglycan-binding proteins 
(PBPs) (Nordmann et al., 2012). These PBPs differ in 2 ways: their affinity to bind to β-
lactams varies, and the quantity of PBPs differ between different species of bacteria 
(Nordmann et al., 2012). According to Nordmann et al. (2012), the β-lactam antibiotic 
structure is similar to that of D-alanyl-D-alanine, which has terminal amino acid deposits on 
the N-acetyl muramique (NAM)/ N-acetyl glucosamine (NAG) peptide subunits of the 
emerging peptidoglycan layer. This similarity allows for the binding of the β-lactams to the 
PBPs active site. 
 
 
The β-lactam nucleus of the molecule can become permanently bound to the Ser403 residue 
of the PBP active site. This will prevent the crosslinking of the new peptidoglycan layer, 
resulting in the disruption of the cell wall synthesis. Usually the peptidoglycan precursors 
signal the reorganisation of the cell wall which encourages the activity of the autolytic cell 
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wall hydrolases. However, if the crosslinking via β-lactams is inhibited; this results in the 
accumulation of peptidoglycan precursors. This involves the assimilation of the existing 
peptidoglycans by autolytic hydrolases in the absence of nascent peptidoglycan. 
Subsequently, the bactericidal action of β-lactam antibiotics are enhanced to a greater extent 




2.2.2. Mechanisms of Resistance 
 
In Enterobacteriaceae, the primary mechanism of resistance is the production of β-
lactamases which hydrolyse β-lactams, while an altered expression of efflux pumps and/ or 
porins is thought to play a minor role (Gazin et al., 2012). Depending on the substrate, the β-
lactamases constitute of four functional groups which are: penicillinases (or classic β-
lactamases), ESBLs, carbapenemases, and AmpC-type cephalosporinases (Dhillon and Clark, 
2009; Gazin et al., 2012). These four groups of β-lactamases are defined according to their 
functions. Penicillinase inactivates penicillin but cannot cause degradation of cephalosporins, 
aztreonam or carbapenems (Dhillon and Clark 2009; Nordmann et al. 2012). 
Cephalosporinase inactivates cephalosporins and aminopenicillins, with the exception of 
penicillins, aztreonam or carbapenems (Dhillon and Clark 2009; Nordmann et al. 2012). 
ESBLs cause inactivation of all β-lactams excluding carbapenems but may be inhibited by 
clavulanic acid, tazobactam, sulbactam, Ethylenediaminetetraacetic acid (EDTA), and 
Sodium Chloride (NaCl). Finally, carbapenemases may selectively inactivate carbapenems 
based on the enzyme produced, and a variety of β-lactam antibiotics (Dhillon and Clark 2009; 
Nordmann et al. 2012).  
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2.2.3. β-Lactamase Inhibitors 
 
Clavulanic acid, sulbactam and tazobactam are β-lactamases inhibitors (Nordmann et al., 
2012). These are derived from β-lactams and are most commonly used for clinical purposes 
unlike other uncommon inhibitors like EDTA and NaCl. The inhibitors have weak 
antimicrobial activity although they share the β-lactam ring trait from β-lactam antibiotics 
(Nordmann et al., 2012). The similarity in the chemical structure of the inhibitory molecules 
allows the substrate to act in a suicidal manner. This occurs by the covalent binding of the 




The resistance of Gram-negative bacteria to antimicrobial agents is increasing rapidly. The 
third generation cephalosporins initially could overcome the resistance caused by β-
lactamases (Paterson, 2006). Third-generation agents such as ceftriaxone, cefotaxime and 
ceftazidime were stable in the presence of classic β-lactamases (Paterson, 2006). However, 
Gram-negative bacilli obtained from hospitals, such as K. pneumoniae, produced mutant 
forms of β-lactamases that made them resistant to both third-generation cephalosporins and 
monobactams (Goossens and Grabein, 2005; Paterson, 2006). Most hospital acquired 
Enterobacteriaceae are resistant to third-generation cephalosporins due to the production of 
β-lactamases. ESBLs that act by hydrolysing both broad- and extended- spectrum 
cephalosporins, monobactams and penicillins, are examples of this resistance (Paterson, 
2006). Therefore, ESBL-producing Enterobacteriaceae in most ICUs are MDR, making it 
difficult to treat nosocomial infections (Gazin et al., 2012; Goossens and Grabein, 2005). 
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Late detection and inappropriate treatment with cephalosporins for illnesses caused by ESBL 
producers, have led to an increase in the mortality rate (Dhillon and Clark, 2009). 
 
 
The genes encoding ESBLs commonly occur in the plasmids that also have genes encoding 
aminoglycoside- and sulphonamide- resistance, are present in numerous Enterobacteriaceae 
(Paterson, 2006). Organisms that produce ESBLs may therefore also be resistant to non-β-
lactam antibiotics such as quinolones, aminoglycosides, and trimethoprim which reduces the 
treatment options (Dhillon and Clark, 2009). ESBLs are transferred by means of a plasmid, 
making it difficult to effectively control and treat organisms that produce this enzyme. 
Another mechanism of resistance in Gram-negative bacteria is the hyperproduction of Bush 
group 1 chromosomally mediated cephalosporinases such as AmpC β-lactamases (Goossens 
and Grabein, 2005). This allows for the resistance to most β-lactams including third-
generation cephalosporins (Goossens and Grabein, 2005). The AmpC-producing strains that 
undergo derepression are the organisms that are often isolated from hospitals, predominantly 
from the ICU (Pfaller and Jones, 2002). This is commonly due to the use of broad-spectrum 
β-lactams (Pfaller and Jones, 2002). The treatment for ESBL- and AmpC- producing 
organisms are the carbapenems. These are the only antimicrobial agents that are active 
against the two mechanisms of resistance described (Goossens and Grabein, 2005).     
 
  
2.3. THE CARBAPENEMS 
 
Carbapenems are a subclass of β-lactam agents and comprise four Food and Drug 
Administration (FDA) approved antibiotics, namely imipenem, doripenem, ertapenem and 
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meropenem (Patel et al., 2009). These antimicrobial agents have been classified into 3 
groups. Ertapenem falls within group 1, which comprises broad-spectrum carbapenems that 
have limited activity against non-fermentative Gram-negative bacilli. This antibiotic is more 
suitable for severe community acquired infections and some hospital acquired infections 
where Pseudomonas spp. and/ or Acinetobacter are not suspected. Group 2 comprises 
imipenem, meropenem and doripenem, which are broad-spectrum carbapenems. These 
antibiotics are active against fermentative and non-fermentative Gram-negative bacilli and 
are appropriate for treatment of severe nosocomial infections. The third group includes 
carbapenems that are clinically active against methicillin-resistant Staphylococcus aureus 
(non-licensed) (Brink et al., 2004; Shah and Isaacs, 2003). 
 
 
Carbapenems have broad spectrum bactericidal activity based on the inhibition of cell wall 
synthesis. Recently, resistance against this group of antimicrobial agents has been 
underscored, from the emergence and spread of ESBL producing Gram-negative bacteria in 
the community and healthcare settings, to an increase in the consumption of carbapenems for 
the treatment of infections with ESBL producers (El-Herte et al., 2012; Nordmann et al., 
2012). In many hospitals, carbapenems have become the first line antimicrobial agents of 
choice for the management of nosocomial infections. These infections are caused by MDR 
strains of Pseudomonas aeruginosa, Acinetobacter species, and ESBL-producing 
Enterobacteriaceae (Patel et al., 2009; Nordmann et al., 2012; Zhang et al., 2012). 
 
 
Carbapenems have a zwitterionic molecular charge which allows the entry of the antibiotic 
through the cell wall of Gram-positive and Gram-negative bacteria (El-Hertea et al., 2012). 
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There are three properties of carbapenems responsible for its broad spectrum of activity (El-
Herte et al., 2012; Parekh and Desai, 2009). Firstly, the molecules are small and have the 
charge characteristic allowing the utilisation of special porins in the outer membrane of 
Gram-negative bacteria gaining access to the PBPs. Secondly, the antibiotic structure confers 
resistance to cleavage by most β-lactamases including carbapenemases. Thirdly, carbapenems 
have an affinity for a broad range of PBPs from various bacteria. These properties allow 
carbapenems to gain access to the periplasm, without being inactivated by β-lactamases, and 
then successfully attaching to PBPs which then results in cell death (Parekh and Desai, 2009). 
This bactericidal activity results in the inhibition of peptidoglycan cell wall synthesis by 
binding to specific PBPs and inactivating the enzymes responsible for the cell wall synthesis 
(Parekh and Desai, 2009). 
 
 
The occurrence of mutations as a result of carbapenem resistance led to a decrease in 
expression of the outer membrane porin protein D (OprD) which prevents the entry of 
imipenem into the bacterium (Knapp and English, 2001). Resistance caused by this type of 
mutation is uncommon in meropenem since it is readily transported through the OprD porin 
(Knapp and English, 2001). If the PBP affinity was modified this would provide an alternate 
mechanism of resistance to carbapenems (Knapp and English, 2001). Similar to other 
carbapenems described, doripenem derives its bactericidal action from the inhibition of PBPs 
which eventually results in cell death (Dong et al., 2012; Gagliotti et al., 2013). The enzymes 
that undergo inhibition due to carbapenems are the high-molecular-weight enzymes PBP1a, 
PBP1b, PBP2, and PBP3 (Matthews and Lancaster, 2009). The inhibition of PBP1a and 
PBP1b leads to the development of spheroplasts and rapid bacterial death. PBP2 enzymes 
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alter rod-shaped organisms by making them spherical, while PBP3 results in the formation of 
filamentous shaped organisms (Matthews and Lancaster, 2009). 
 
 




The chemical structure of ertapenem has a trans hydroxyethyl group (as shown in Fig. 1) of 
the molecule (not found in other carbapenems) which contributes to the stability of this class 
of anti-infectives to β-lactamases (Motyl et al., 2003). Ertapenem is a long-acting 1-β-methyl 
carbapenem. The 1-β-methyl group protects the β-lactam carbonyl which reduces the 
Dehydropeptidase-1 (DHP-1) catalysed hydrolysis of the β-lactam ring and allows for the 
administration of ertapenem, independently (Motyl et al., 2003). The meta-substituted 
benzoic acid complex increases the molecular weight and lipophilicity of the molecule, and 
the carboxylic acid, ionised at physiological pH, gives ertapenem a net negative charge 
(Motyl et al., 2003). Therefore, protein binding in ertapenem is greater compared to that of 
imipenem and meropenem, resulting in an extended half-life. Similar to other β-lactam 
antimicrobial agents, ertapenem has the ability to inhibit the synthesis of bacterial cell wall 
peptidoglycan layer by binding to PBPs. In E.coli, it binds to PBP1a, 1b, 2, 3, 4, and 5, with a 
high affinity of PBP2 and 3 (Motyl et al., 2003).        
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Fig. 1: Chemical structure of ertapenem (Sigma-Aldrich) 
 
 
Ertapenem is not extensively hydrolysed by β-lactamases and acts against a wide variety of 
Gram-positive, Gram-negative, and anaerobic microorganisms, in particular 
Enterobacteriaceae (Bora et al., 2012). However it provides limited activity against P. 
aeruginosa, and Acinetobacter spp., normally associated with nosocomial infections 
(Borbone et al., 2006). Ertapenem is used for the treatment of infections such as intra-
abdominal, skin-to-skin structure, urinary tract, acute pelvic infections and acquired 





Imipenem, N-formimidoylthienamycin (shown in Fig. 2), was the first type of carbapenem 
derived from a stable and synthetic drug, known as thienamycin (Knapp and English, 2001). 
In an early study by Jacobs (1986), imipenem was metabolised in conjunction with the 
tubular brush border by the DHP-1 enzyme. This accounts for the renal tubular damage 
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observed in animal studies as well as low recovery of imipenem in the urine of humans 
(Knapp and English, 2001). In other human studies, it was found that imipenem had to be 
produced with cilastatin sodium (a reversible inhibitor of DHP-1) that has no intrinsic 
antibacterial properties (Knapp and English, 2001). Therefore, when imipenem is 
administered to a patient it has to be co-administered with cilastatin in order to inhibit the 
action of DHP-1 (Darville, 1999). Notably, the imipenem/ cilastatin combination was 
reported to induce seizures in humans at clinical doses. The convulsive action of this β-
lactam antibiotic may be associated with their ability to inhibit the binding of the γ-
aminobutyric acid receptor (Horiuchi et al., 2006).  
 
 
Fig. 2: Chemical structure of imipenem (Sigma-Aldrich) 
 
 
Imipenem has a high binding affinity in vitro to PBP2 and PBP4 in P. aeruginosa and 
inhibits the enzyme activities of PBP1a, PBP1b, PBP2, PBP4 and PBP5 in E. coli. PBP2 is 
responsible for the rod-shaped morphology of the cells and is the binding site of several β-
lactam antibiotics which in turn contributes to their resistance (Song et al., 1998). Inhibition 
of PBP3 in Pseudomonas spp. influences a greater number of genes involved in transcription, 
DNA repair, transcription of pyocin genes and genes implicated in antibiotic resistance 
(Farra, 2008).   
 




Meropenem is an ultra-broad spectrum injectable antibiotic of the carbapenem group. It was 
the first carbapenem antibiotic that exhibited resistance to hydrolysis by DHP-1, hence there 
is no need for the co-administration of a DHP-1 inhibitor (Parekh and Desai, 2009). Although 
the main carbapenem nucleus has a β-lactam ring, which differs from penicillin and 
cephalosporins, the sulphur on the side chain is substituted with a methylene group and the 
ring contains a double bond (shown in Fig. 3) (Parekh and Desai, 2009). These differences 
confer meropenem resistance to degradation by the usual β-lactamases and the ESBLs, as 
well as chromosomally produced AmpC β-lactamases (Parekh and Desai, 2009). This 
structure also has a long substitute pyrroline side chain at C-2 which enhances its activity 
against P. aeruginosa (Darville, 1999). Meropenem has the ability to readily penetrate 
various Gram-negative organisms, accounting for its enhanced activity against these bacteria 
(Knapp and English, 2001).  
 
 
      








Doripenem is a synthetic 1-β-methyl carbapenem antibiotic that has a broad-spectrum of 
activity (Goldstein and Citron, 2009). Its structure provides stability against DHP-1 and 
various other β-lactamases. Doripenem displays potent antibacterial activity against both 
Gram-negative and Gram-positivebacteria, whilst meropenem is active against Gram-
negative bacteria (Goldstein and Citron, 2009; Horiuchi et al., 2006). Doripenem has a 
sulfamoylaminoethyl-pyrrolidinylthio group (in its side chain) at the second position (as 
shown in Fig. 4) (Gales et al., 2011). This enhances its activity against non-fermentative 
Gram-negative bacilli. According to Gales et al. (2011), doripenem is stable against the 
hydrolysis by most β-lactamases, including penicillinases and cephalosporinases, but not to 
carbapenem hydrolysing β-lactamases.  The PBPs that are preferentially bound by doripenem 
vary with different organisms. In E.coli, doripenem prefers to bind to PBP2, followed by 
PBP1a, 1b, and then 3. In P. aeruginosa, doripenem binds to PBP2 and 3 first and then 
PBP1a and1b. However, with Streptococcus pneumoniae, doripenem has high affinity 
towards PBP1a, 2b and 2x (Matthews and Lancaster, 2009).  
 
 
Fig. 4: Chemical structure of doripenem (Sigma-Aldrich) 
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Doripenem is active against ESBLs and AmpC producing Enterobacteriaceae (Castanheira et 
al., 2009; Dong et al., 2012). It displays the highest activity toward P. aeruginosa in terms of 
MIC values. This is possible because doripenem retains activity against strains with 
resistance to other carbapenems via the loss of OprD alone or in combination with efflux 
pumps (Castanheira et al., 2009). According to Goldstein and Citron (2009), anaerobes are 
unable to use efflux pumps as resistance mechanisms against doripenem. In vitro studies 
proved that this antibiotic was reported as restricted in its selection for resistant strains. In 
general, its activity is less potent than imipenem, but more potent than meropenem, against 
Gram-positive bacteria (Gales et al., 2011). However, the activity of doripenem against 
Gram-negative bacteria was reported as being similar to that of meropenem but much greater 
than imipenem (Gales et al., 2011).  
 
 
2.4. CARBAPENEM-RESISTANT ENTEROBACTERIACEAE (CRE) 
 
2.4.1. Non-Carbapenemase Mediated CRE 
 
2.4.1.1. ESBL Production 
 
In Enterobacteriaceae, resistance may develop due to a combination of ESBLs and outer 
membrane permeability defects being produced. In this case, genes such as blaTEM, blaSHV, 
and blaCTX-M, that code for ESBLs, are found on a  plasmid (Qin et al., 2008). This 
mechanism of resistance was observed in almost all Enterobacteriaceae, including E. coli, K. 
pneumoniae, Salmonella spp., and Enterobacter spp. According to Nordmann et al. (2012), 
ertapenem-resistant and ESBL-producing K. pneumoniae (observed in Italy) carried OmpK36 
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porin variants which played a role in its resistance (Nordmann et al., 2012). The resistance to 
ertapenem was related to the reduction in the susceptibility to meropenem and imipenem. 
Ertapenem-resistant isolates developed due to the distribution of CTX-M-producing isolates  
globally (Pitout and Laupland, 2008).  
 
 
2.4.1.2. Outer Membrane Impermeability and Efflux 
 
Gram-negative bacteria have a hydrophobic outer membrane which prevents external agents 
from entering the cell. The membrane comprises proteins known as porins which allow the  
hydrophilic pathways to acquire necessary nutrients and compounds, such as antibiotics 
(Koebnik et al., 2000; Pagès et al., 2008). In Enterobacteriaceae, the porins responsible for 
the uptake of antibiotics belong to outer-membrane protein F (OmpF) or outer-membrane 
protein C (OmpC) family. If the number or the activity of the porins are altered this could 
affect antibiotic resistance (Nordmann et al., 2012). A reduction in the sensitivity of the 
antibiotics may occur as a result of mutations in the gatekeeping loop or central channel 
within the porin proteins, a lack of porin expression, or an alteration in the type of porins 
present in the outer membrane (Patel et al., 2009).  
 
 
Carbapenem resistance was initially observed in Enterobacter spp. which overexpressed a 
chromosomal ampC gene encoding an intrinsic cephalosporinase and showed altered OmpC 
and OmpF porins (Nordmann et al., 2012). This mechanism was also detected in other 
species from the family of Enterobacteriaceae that do not express the intrinsic 
cephalosporinase such as E. coli, K. pneumoniae and Salmonella spp. In these organisms, 
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resistance prevailed due to the linking of plasmid-encoded AmpC expression with a decline 
in cell membrane permeability (Armand-Lefevre et al., 2003; Chia et al., 2009; Shin et al., 
2012). This was due to the modified OmpK35 or OmpK36 for K. pneumoniae, OmpF and 
OmpC for E. coli, and OmpF for Salmonella typhimurium (Armand-Lefevre et al., 2003; 
Chia et al., 2009; Shin et al., 2012). Plasmid-mediated cephalosporinase genes are usually 
related to co-resistance to other antibiotics as a result of the co-localisation of antibiotic 
resistance genes on the same plasmid (Nordmann et al., 2012). According to Patel et al. 
(2009), carbapenem resistance in organisms with porin deficiencies are unstable due to a 
reduction in fitness and growth ability of organisms that have a defect in terms of the 
permeability barrier of the outer membrane (Patel et al., 2009). 
 
 
Reports done on carbapenem resistance in Klebsiella spp. associated with porin loss in 
combination with SHV ESBLs, showed undetectable carbapenemase activity in vitro. The 
ability of weak carbapenemases to confer resistance in impermeable strains differs from the 
inability of strong carbapenemases to confer substantial resistance in highly permeable 
isolates. Strains that lack carbapenemase production but are resistant to carbapenems are 
normally susceptible to other antibiotics. This carbapenem resistance characteristic may not 




The efflux of antibiotics to the exterior of the bacteria through the production of an efflux 
pump also leads to resistance to various antimicrobial agents including the carbapenems 
(Nordmann et al., 2012). Imipenem selects strains that contain the active efflux pumps that 
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eject various unrelated antibiotics including quinolones, tetracycline, and chloramphenicol. 
The overexpression of the AcrA efflux pump component was reported in Enterobacter 
aerogenes and was responsible for imipenem resistance (Bornet et al., 2003). The 
overexpression of marA, involved in the genetic control of membrane permeability via porin 
and efflux pump expression, showed that the activation of the resistance genes are forced in 
imipenem resistant variants (Bornet et al., 2003).   
 
 
2.4.1.3. AmpC Production 
 
Another non-carbapenemase mediated resistance mechanism was evident in a few 
carbapenem-resistant isolates that expressed AmpC-type enzymes in combination with porin 
loss (Patel et al., 2009; Qin et al., 2008). The AmpC-type enzymes confer resistance to 
extended-spectrum cephalosporins and have low carbapenem activity. However, when this 
enzyme activity is combined with decreased cellular penetration of carbapenems as a result of 
porin loss then carbapenem resistance is observed (Patel et al., 2009). Similar activity was 
observed in Enterobacteriaceae, where carbapenem resistance was observed in isolates that 
had ESBLs and porin loss (Patel et al., 2009). In this case, β-lactamase had the ability to 
confer resistance in strains that had reduced uptake or up-regulated efflux in the absence or 
presence of weak carbapenemase activity (Livermore and Woodford, 2000). These organisms 
may be able to express susceptibility to various types of carbapenem agents (Livermore and 
Woodford, 2000).  
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Imipenem resistance related to porin loss and the hyperproduction of chromosomal AmpC β-
lactamase was observed in Enterobacter spp. (Livermore and Woodford, 2000). However, 
imipenem resistance due to porin loss and the presence of plasmidic AmpC β-lactamase was 
evident in K. pneumoniae (Livermore and Woodford, 2000). Organisms that are responsible 
for the hyperproduction of AmpC due to mutation or plasmid encodement are usually 
resistant to most cephalosporins and monobactams but are not inhibited by β-lactamase 
inhibitors (Denton, 2007; Qin et al., 2008). According to Livermore and Woodford (2000), 
AmpC β-lactamase displayed weak activity against imipenem, however this mechanism was 




El-Hertea et al. (2012) undertook a study involving dual resistance mechanisms which 
involved the outer membrane permeability defect with the production of β-lactamases, such 
as AmpC, cephalosporinases and ESBLs, predominantly in the presence of CTX-M variants. 
It is not necessary to detect for the production of AmpC organisms that produce an inducible 
chromosomal AmpC β-lactamase. This is because the organisms that are assumed to be 
carriers of the AmpC enzymes are known and include 100% of Enterobacter cloacae, E. 
aerogenes, Citrobacter freundii, Serratia marcescens, Providencia spp., Morganella 
morganii, Aeromonas spp. and P. aeruginosa (Thomson, 2010). These organisms possess the 
ability to readily mutate in order to confer resistance during treatment with β-lactam 
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2.4.2. Carbapenemase Production 
 
Carbapenem-resistant bacteria in the healthcare setting restrict treatment of nosocomial 
infections. The emergence of carbapenem-inactivating β-lactamases (i.e. carbapenemases) 
has recently emerged and was reported in pathogenic Enterobacteriaceae in various parts of 
the world (Patel et al., 2009). Carbapenemases confer resistance to β-lactam agents and are 
usually found in mobile genetic elements that allow for the transfer of resistance mechanisms 
from one isolate to the next. However, organisms that produce this enzyme may also spread 
among patients (Patel et al., 2009). The coexistence of ESBL and carbapenemase genes with 
other antibiotic resistance genes on mobile genetic elements is a major concern. This, coupled 
with the plasticity of Enterobacteriaceae, results in the rapid acquisition of resistance to new 
classes of antibiotics. The uncontrollable transfer of intra- and inter-species of mobile genetic 
elements has also contributed to the emergence of organisms with resistance to almost all 
antibiotics (Gazin et al., 2012). There are three crucial factors that distinguish the emerging 
carbapenemase associated resistance from early ESBL resistance (Livermore, 2012). Firstly 
there is no apparent next line antibiotic to use against carbapenemase-producers (the way 
carbapenems were used for ESBL-producers). Secondly, detection is difficult because the 
problem has reduced since the prevalence of carbapenemases are lower compared to other 
ESBLs and the rapid detection methods still require optimisation. Finally, carbapenemase-
producers are more diverse in terms of enzymes, species and epidemiology, which 
complicates the development of inhibitor-based responses by the pharmaceutical industry 
(Livermore, 2012).            
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The first type of carbapenemases discovered was SME-1 found in Enterobacteriaceae in 
London in 1982 and IMI-1 was found in the US in 1984 (Rasmussen et al., 1996). Serine-
based carbapenemases, originated from the chromosomally-encoded NmcA from the clinical 
isolate E. cloacae (the first to be reported in literature) (Rasmussen et al., 1996). Since then, 
the dissemination of carbapenem resistance has increased significantly, primarily due to the 
triggering of carbapenemase production. The new classes of carbapenemases were first 
discovered in Gram-negative bacteria in Japan in the 1990’s and the first clinically significant 
isolate was found in Europe, Italy in 1999 (Zimmerman et al., 2013).  
 
 
The emergence of carbapenemases in Enterobacteriaceae is of great concern since these 
pathogens occur frequently and the diversity of enzymes is rapidly emerging. This makes 
recognition, treatment and response problematic (Livermore, 2012). In Enterobacteriaceae, 
carbapenemases are divided into three main molecular classes of β-lactamases, these include: 
Ambler class A, which comprises Klebsiella pneumoniae carbapenemase (KPC); class B 
metallo-β-lactamases, which comprises Verona integron-encoded metallo-β-lactamases 
(VIM), imipenemase (IMP), and New-Delhi metallo-β-lactamases (NDM); and class D 
carbapenemase, which comprises Oxacillinase (OXA-48) (Dhillon and Clark, 2009; 
Livermore, 2012; Nordmann et al., 2012). The Ambler class C (AmpC) may also fall within 
these classes however it is a rare chromosome-encoded cephalosporinase. 
 
 
Resistance mechanisms of metallo-β-lactamases of VIM and IMP families were described in 
Europe. In the USA, a carbapenemase-producing organism that was resistant to serine-based 
carbapenemases was first described in K. pneumoniae in 2001 (Zimmerman et al., 2013). 
- 28 - 
 
This resistance mechanism was transmitted to other Enterobacteriaceae via K. pneumoniae. 
In Israel in 2007, the CRE triggered were similar to that found in USA, primarily due to KPC 
in K. pneumoniae (Zimmerman et al., 2013). According to Nordmann et al. (2012), there are 
two main mechanisms responsible for the production of CREs. The first mechanism entails 
the acquisition of carbapenemase genes that encode carbapenem degrading enzymes. The 
second mechanism involves the reduction in antibiotic uptake by a qualitative and/ or 
quantitative absence of porin expression associated with over expression of β-lactamases with 
a weak affinity for carbapenems.  
 
 
2.4.2.1. Ambler Class A Carbapenemases 
 
Class A serine-based carbapenemases can be subdivided into three major types of 
chromosomally encoded enzymes including NmcA/ IMI, SME, and KPC (Livermore and 
Woodford, 2000; Nordmann et al., 2012; Patel et al., 2009). These enzymes have the ability 
to hydrolyse various β-lactams such as penicillins, cephalosporins, carbapenems, and 
aztreonam (Nordmann et al., 2012; Patel et al., 2009). They are susceptible to different types 
of inhibitors. Whilst all enzymes are weakly inhibited by sulbactam, the IMI and NmcA 
enzymes are inhibited strongly by clavulanate but the SME carbapenemases are not inhibited 
(Rasmussen and Bush, 1997). This hydrolytic mechanism involves the active serine site at 
position 70 (Ambler numbering of class A β-lactamases) and the activity is inhibited in vitro 
by clavulanic acid and tazobactam (Ambler et al., 1991). The SME enzymes have been 
identified exclusively in S. marcescens (Patel et al., 2009). This family comprises three 
variants (SME-1, SME-2, and SME-3) that are chromosomally-encoded and are found 
infrequently in USA (Naas et al., 1994; Nordmann et al., 2012).  
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IMI and NmcA enzymes were recovered from rare isolates of Enterobacter spp. in the UK, 
France, and Argentina (Nordmann et al., 2012; Patel et al., 2009). The gene responsible for 
encoding the IMI-2 variant was located in the plasmid of Enterobacter asburiae strains found 
in a river in the USA, as well as one strain of E. cloacae in China (Nordmann et al., 2012). 
The genes encoding SME, IMI, and NmcA enzymes that are located in the chromosome and 
the lack of association with mobile genetic elements have resulted in their limited distribution 
(Queenan et al., 2000; Rasmussen et al., 1996). Another type of carbapenemase that belongs 
to this class is known as the Guiana extended-spectrum β-lactamase (GES) (Brink et al., 
2012a). According to Brink et al. (2012a), GES was identified in various isolates in several 
hospitals in South Africa: K. pneumoniae in Cape Town, K. oxytoca in Bloemfontein, E. 
cloacae in Witbank, and S. marcescens in Port Elizabeth.    
  
 
In class A β-lactamases, the most clinically significant enzyme is KPC since it is most 
frequently encountered (Arnold et al., 2012; Patel et al., 2009). KPC was first described in 
the USA and is now found globally. Its variant, KPC-2, was identified in K. pneumoniae in 
1996 in Eastern USA (Bulik et al., 2010). Ever since, 11 KPC variants were observed, 
ranging from KPC-2 to KPC-12 (Nordmann et al., 2012). KPC-2 was observed in K. 
pneumoniae in Johannesburg, South Africa in 2012 (Brink et al., 2012a). These enzymes 
were primarily acquired from nosocomial isolates of K. pneumoniae and others from 
Enterobacteriaceae species (Bulik et al., 2010). The subtype KPC-1 also exists which 
harbours genes that are identical to that of KPC-2 (Bulik et al., 2010; Patel et al., 2009). 
KPC-4 was initially discovered in Enterobacter spp. in Scotland in 2004 and was reported in 
K. pneumoniae in Puerto Rico (Patel et al., 2009). The hydrolytic profiles of both KPC-2 and 
KPC-3 are similar since they both possess a higher affinity for meropenem when compared to 
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imipenem. However, in KPC-3 there is evidence of higher hydrolysis of ceftazidime (Patel et 
al., 2009).  
 
 
According to Livermore (2012) recently, non-clonal K. pneumoniae were responsible for the 
spread of plasmids encoding KPC enzymes in the UK. The mortality rate, as a result of the 
spread of infection by KPC producing organisms, increased to over 50%. A possible reason 
for this occurrence may be due to MDR organisms harbouring the KPC enzymes (Nordmann 
et al., 2012). This may result in first line therapy failing and limits the therapeutic options 
(Nordmann et al., 2012). KPC-producers have varying susceptibility patterns, but many 
studies have proved that when blaKPC (an enzyme-encoding gene) is transferred to a 
susceptible E. coli then the enzyme will confer resistance to all β-lactam agents (Patel et al., 
2009). A clone of K. pneumoniae strain ST258 expressing the blaKPC-2 was identified globally 
and was the cause for the geographical dissemination of the blaKPC (Cuzon et al., 2010). 
However, various other KPC clones may have spread in the same region but differ in 
multilocus sequence type, β-lactamase content, and plasmid size (Nordmann et al., 2012). β-
lactamase inhibitors are active against KPC enzymes but this activity is low, allowing the 
KPC-producers to confer resistance to all β-lactam-β-lactamase inhibitor combinations (Patel 
et al., 2009; Villegas et al., 2006). This includes ampicillin-sulbactam, amoxicillin-clavulanic 
acid, and piperacillin-tazobactam combinations (Patel et al., 2009).  
 
 
The spread of the blaKPC may be partially due to their presence on the plasmid. KPC encoding 
plasmids (some of which are conjugative) harbour alternate mechanisms of resistance 
including: β-lactamases, plasmid-mediated flouroquinolone resistance, and aminoglycoside 
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resistance (Patel et al., 2009). A 95 kb plasmid carrying the blaKPC was found in 2 different 
species of Enterobacteriaceae, namely C. freundii, and Klebsiella oxytoca (Rasheed et al., 
2008). These strains were isolated from two different patients in the same hospital (Rasheed 
et al., 2008). The transfer of this plasmid may have occurred due to interspecies transfer 
within the hospital. According to Nordmann et al. (2012), there is evidence that the blaKPC 
are associated with the genetic element otherwise known as the transposons Tn4401. This 
transposon is Tn3-like and was found in isolates of various geogFraphical origins and differ 
in terms of sequence types in Enterobacteriaceae and P. aeruginosa (Yang and Bush, 1996). 
Tn4401 is usually introduced at different loci as well as on the plasmids of different sizes and 
incompatibility group (Arnold et al., 2011; Patel et al., 2009). This transposon undergoes 
transposition which results in the formation of a duplicate 5-bp target site which has a non-
specific target site (Arnold et al., 2011; Patel et al., 2009).  
 
 
2.4.2.2. Class B Metallo-β-Lactamases 
 
The class B metallo-β-lactamases display hydrolytic activity against penicillins, 
cephalosporins and carbapenems yet it is not inhibited by β-lactamase inhibitors (Nordmann 
et al., 2012). This hydrolytic activity depends on the interaction of β-lactams with Zn
2+
 ions 
as a cofactor in the active site and is therefore inhibited by EDTA (Patel et al., 2009). The 
first metallo-β-lactamase (MBL) was identified in environmental and opportunistic bacteria 
such as Bacillus cereus, Aeromonas spp., and Stenotrophomonas maltophilia. The MBL 
genes within these pathogenic organisms are intrinsically and chromosomally-encoded 
(Iaconis and Sanders, 1990; Kuwabara and Abraham, 1967; Lim et al., 1988; Yang and Bush, 
1996). Since the 1990’s, a drastic increase in the acquisition or transference of MBL genes 
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were reported in Enterobacteriaceae, which included IMP, VIM and NDM groups (Iaconis 
and Sanders, 1990; Yang and Bush, 1996)).  
 
 
IMP was one of the first MBLs identified and detected in Pseudomonas spp., Acinetobacter 
spp., and Enterobacteriaceae (Patel et al., 2009). In Japan in 1991, the IMP-1 variant was the 
first of these types of genes to be reported in S. marcescens as well as a single variant in K. 
pneumoniae (Ito et al., 1995). Since the 1990’s, 33 IMP variants have emerged and have 
spread worldwide (Nordmann et al., 2012). The selection of numerous IMP-type genes in 
Japan may have been possible due to the over use of carbapenems. IMP-1, -2, and -3 
enzymes have broad activity against β-lactams with the exception of monobactams 
(Livermore and Woodford, 2000). IMP-1 may be relatively more active against carbenicillin 
than ampicillin, while IMP-2 and IMP-3 display similar activity against both these antibiotics 
(Livermore and Woodford, 2000). Isolates that have IMP-type β-lactamases express the 
blaIMP which reveal features of class 1 integrons (Zhao and Hu, 2011).  
 
 
The class 1 integrons are structures of DNA that have antibiotic resistance genes called gene 
cassettes that are co-expressed from a single promoter. These resistance genes code for 
reduced susceptibility to dissimilar antibiotic molecules such as β-lactams, aminoglycosides, 
sulphonamides, and chloramphenicols. The genes from the integrons containing the blaIMP 
are known for encoding aminoglycoside resistance (aacA4, aadA1, and aadB), 
chloramphenicols (catB), and class D β-lactamases (blaOXA). Class 1 integrons normally 
occur within the transposon structure allowing their dispersion (Zhao and Hu, 2011). 
However, it may integrate resistance genes that are unrelated but are mobile on their own 
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(Zhao and Hu, 2011). The relationship between blaIMP alleles and carbapenem resistance is 
flawed, and some blaIMP hosts are susceptible (Livermore and Woodford, 2000). This may be 
possible due to blaIMP not being expressed frequently, or because substantive resistance may 
require reduced uptake of carbapenems and the presence of β-lactamase enzymes (Livermore 
and Woodford, 2000).  
 
 
The variants of the VIM enzymes is the next type of MBL, from which VIM-1 originated in 
Italy in 1997 and sometime later, VIM-2 emerged in France from P. aeruginosa isolates. 
VIM-2 enzymes have a 90% amino acid homology to VIM-1 (Takahashi, 2000). The VIM 
group of enzymes eventually made up 33 variants, majority of which were observed in P. 
aeruginosa and the remainder in Enterobacteriaceae. Similar to IMP-type genes, these genes 
correspond to the gene cassettes found inside the class 1 integrons. VIM-2 was associated 
with 45 kb non-conjugative plasmid, whereas VIM-1 was not associated with extra 
chromosomal DNA (Livermore and Woodford, 2000). VIM-2 is the most commonly reported 
MBL found worldwide, with the greatest prevalence in Southern Europe and Southeast Asia. 
The clonal spread of K. pneumoniae encoding VIM carbapenemases occurred around the UK, 
which explains the prevalence of KPC enzymes between the year 2010 and 2011 in this 
region (Livermore, 2012). VIM was also detected in K. pneumoniae in South Africa, 
Johannesburg (Brink et al., 2012a). 
 
 
The final family of MBLs is NDM, from which NDM-1-positive Enterobacteriaceae variants 
emerged. NDM-1 was originally identified in an Indian patient in Sweden in 2008 
(previously hospitalised in New Delhi). Since then, NDM-1-producers have also spread 
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throughout the world (Livermore, 2012). India is referred to as the reservoir of the blaNDM-1, 
since the majority of the patients that have acquired the NDM-1 producers have either 
travelled to the Indian subcontinent or have been in contact with India, Pakistan or 
Bangladesh (Livermore, 2012; Potron et al., 2011b). Many other Enterobacteriaceae isolates 
that produce NDM variants were identified in patients that had relationships with Balkan 
states or the Middle East (Livermore, 2012). This implies that this region could be the 
secondary reservoir of NDM-1 producers. An E. cloacae producing NDM-1 strain was 
recently detected in Pretoria, South Africa (Brink et al., 2012a). The transmission of NDM-1 
enzyme differs from other carbapenemases. The plasmids that encode the NDM-1 gene have 
a broad range of hosts which allows for the easy dissemination among other 
Enterobacteriaceae and unrelated species (Coetzee and Brink, 2011). According to Govind et 
al. (2013), organisms that produce blaNDM-1 are able to colonise the gastrointestinal tract of 
humans for an extended duration. These are normally spread via contaminated water and 
environmental surfaces which was similar to that observed in the current surveillance. 
 
 
Studies reported that the spread of blaNDM-1-producing Enterobacteriaceae was not associated 
with any of the following: transmission of specific clones, the transfer of specific plasmids, or 
the distribution of a given genetic structure (Poirel et al., 2011). Therefore it may be 
identified from different Gram-negative organisms carried by a variety of plasmids 
(Nordmann et al., 2012). Plasmids that harbour the blaNDM-1 are diverse in size, 
incompatibility group, and its association with resistance genes (Nordmann et al., 2012). 
NDM normally have plasmid AmpC-β-lactamases and ESBLs in combination with the ArmA 
and/ or RmtC methylases that alter the 16S rRNA in order to block the binding of most 
aminoglycosides (Livermore, 2012).  
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All NDM-1 producers possess the ability to express various unrelated resistance genes like 
those encoding carbapenemases (VIM-type, OXA-48-type), AmpC, cephalosporinases, 
ESBLs; and resistance to aminoglycosides (16S RNA methylases), macrolides (esterases), 
rifampicin (rifampicin-modifying enzymes) and sulfamethoxazole (Nordmann et al., 2012). 
This association with such a large number of plasmids and chromosomes that code for 
resistance genes in single isolates are uncommonly reported, but is the primary reason for the 
emergence of MDR isolates. Several NDM-1 producers are susceptible to fosfomycin, 
colistin, and tigecycline. However, the spectrum and side effect profile of these agents limit 
its utility in the management of infections with MDR isolates. In addition, there have been 
recent reports of infection with organisms that are resistant to all available antibiotics 
(Nordmann et al., 2012). 
 
 
In recent years, an association with blaNDM-1 and bleMBL (encodes functional bleomycin 
resistance protein) was reported (Dortet et al., 2012). These two genes share the same operon 
and are co-expressed by the same promoter, with bleMBL being partially developed by the 3’ 
end of the insertion sequence ISAba125 (Dortet et al., 2012). The production of bleomycin 
resistance proteins reduces the rate of mutations of the recA, which in turn stabilises the 
blaNDM-1 positive isolates (Nordmann et al., 2012). This means that the emergence of 
carbapenem-resistant NDM-1 may be chosen by bleomycin type molecules produced by the 
environmental organism Streptomyces spp. These strains have proteins that encode 
bleomycin resistance due to the development of the NDM genes. This may result in its 
persistence in the environment due to the selection by bleomycin-related molecules 
developed in nature (Nordmann et al., 2012).  
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2.4.2.3. Class D Carbapenemases 
 
OXA is a type of class D β-lactamase enzyme that is classified phenotypically because of its 
oxacillinase activity (Livermore and Woodford, 2000; Nordmann et al., 2012; Poirel et al., 
2012a). This enzyme comprises 232 variants that have carbapenemase resistance (Livermore 
and Woodford, 2000; Nordmann et al., 2012; Poirel et al., 2012a). OXA was found in 
Mediterranean countries and is currently circulating to other geographical areas. The first 
organism that produced OXA-48 was identified in a K. pneumoniae isolate in Turkey in 2003 
(Livermore, 2012). OXA-48 producers were sourced from nosocomial infections which 
spread throughout Turkey and were prevalent in Southern Europe and North Africa. 
Organisms producing OXA-48 such as K. pneumoniae, E. coli, or E. cloacae were reported in 
nosocomial transmission amongst patients in France, Germany, Spain, Netherlands, and the 
UK (Poirel et al., 2012a). OXA-48 and its derivatives were also reported among 
Enterobacteriaceae in hospitalised patients in Johannesburg, Cape Town and Port Elizabeth 
(Brink et al., 2012a).  
 
 
Carbapenem-hydrolysing class D β-lactamases (CHDLs) are unable to hydrolyse extended-
spectrum cephalosporins, with the exception of the OXA-163 variant which has weak 
carbapenemase activity (Nordmann et al., 2012; Poirel et al., 2012a). OXA-2 and OXA-10 
have the ability to yield mutants that attack oxyimino-aminothiazolyl cephalosporins but lack 
carbapenemase activity (Livermore and Woodford, 2000). In general, the carbapenemase 
activity of CHDLs is weak and can be inhibited by NaCl but not clavulanic acid or EDTA 
(Nordmann et al., 2012). Majority of the CHDLs variants were observed in Acinetobacter 
spp. but OXA-48 was found in Enterobacteriaceae only (Poirel et al., 2012a). 
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The blaOXA-48 is spread among Enterobacteriaceae via a single plasmid which is 62 kb in size 
(Potron et al., 2011a). This plasmid is self-conjugative and has an IncL/ M type backbone 
that lacks other genes required for antibiotic resistance (Poirel et al., 2012a). The blaOXA-48 is 
bracketed by two IS1999 elements in order to form a functional composite transposon (Poirel 
et al., 2012b). Another type of gene responsible for resistance (identical to the blaOXA-48 in 
terms of hydrolytic properties) is the blaOXA-181 (Poirel et al., 2012b). This gene is a point-




The blaOXA-181 is positioned on a non-conjugative ColE2 type plasmid (7 kb in size) when 
associated with the insertion sequence ISEcp1 (Potron et al., 2011c). This ISEcp1 is 
responsible for acquiring the gene by means of one-ended transposition mechanism (Potron et 
al., 2011c). Shewanella oneidensis harbours the blaOXA-48 while Shewanella xiamenensis 
holds the blaOXA-181 (Poirel et al., 2004; Potron et al., 2011d). The transfer of the resistance 
gene among Shewanella spp. and Enterobacteriaceae may be a result of these organisms 
residing in the same water-borne environment. The organisms that produce OXA-48 and 
OXA-181 normally do not display high levels of resistance to the carbapenems. This may be 
problematic for detecting the OXA-48-like enzymes unless those organisms have 
mechanisms that are associated with resistance such as ESBL production and/ or permeability 
defects (Nordmann et al., 2012). Numerous strains that harbour the OXA-48 enzyme produce 
resistance through co-production of ESBLs and tend to lack activity against oxyimino-
cephalosporins (Livermore, 2012).         
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2.5. JUSTIFICATION OF THE STUDY 
 
Carbapenemases are the primary cause for the increase in carbapenem-resistance in Gram-
negative Enterobacteriaceae (Bush et al., 2013). Carbapenems are frequently used to treat 
nosocomial infections caused by microorganisms that are resistant to all other classes of 
antibiotics. Carbapenemases not only have the ability to render the potent carbapenem group 
of antibiotics inactive, but are also able to inactivate unrelated groups of antibiotics. The 
bacteria that produce carbapenemases have become a major threat in hospitals globally, and 
present a management dilemma in selecting appropriate and effective antibiotics (Bush et al., 
2013). This adversely impacts the morbidity and mortality in patients with nosocomial 
infections.   
 
 
Carbapenem-resistance in South Africa has only been reported in the context of CPEs 
(Coetzee and Brink, 2011). K. pneumoniae and E. cloacae harbouring the NDM and KPC 
enzymes were initially isolated (Brink et al., 2012b). To date the most common enzymes in 
South Africa includes GES, KPC, MBLs, NDM-1, and OXA-48 (Brink et al., 2012b). In the 
private sector, the use of imipenem, meropenem and ertapenem has exceeded its monthly 
units sold by more than 50%, between January 2009 and June 2011 (Coetzee and Brink, 
2011). The excessive consumption of these antibiotics, through selective pressure, has led to 
the development of carbapenem resistance among Enterobacteriaceae and in turn CPEs. In 
South Africa multiple outbreaks and epidemics have been reported with regard to these CPEs 
(Brink et al., 2012b; Coetzee and Brink, 2011). 
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The focus on efforts to control the spread of these organisms centre around the rapid 
detection of the organisms and isolation of patients. The genes responsible for the transfer of 
these enzymes may become endemic in hospitals, with eradication becoming unattainable, 
regardless of the intensive infection control measures. As a result, the timeous detection of 
CPEs and appropriate isolation of patients is considered to be of critical importance in 
stemming the spread of these highly resistant organisms. However, the enzymes conferring 
carbapenemase resistance are usually produced together with other enzymes of the β-
lactamase group, making individual carbapenemase detection difficult with simple 
phenotypic tests. Therefore further research is required to determine the appropriate 
techniques for the rapid detection of CPEs and the mechanisms of action used by these 
organisms to develop antibiotic resistance. Such resistance may be alleviated through 
aggressive infection control measures and optimisation of antibiotic therapy, which could 
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CHAPTER THREE 
MATERIALS AND METHODS 
 
3.1. ETHICS APPROVAL  
 
This study was approved by the Biomedical Research Ethics Committee at the University of 
KwaZulu-Natal under the ethics number BE222/13 and the KZN Provincial Research 
Committee (Appendix A).   
 
 
3.2. STUDY SITE AND PATIENTS 
 
The study was conducted in the neonatal nursery at King Edward VIII Hospital, Durban, 
KwaZulu-Natal, South Africa. King Edward VIII hospital is a regional hospital that delivers 




The nursery at King Edward VIII has 3 Neonatal Intensive Care Unit (NICU) beds, 4 high 
care beds and 10 servo-cribs and 15 incubators. The clinical indication for admission to the 
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3.3. SPECIMEN COLLECTION  
 
Specimens were collected from neonates in the following wards: Observation 1, Old 
premature nursery and New premature nursery (Appendix B, Table 1). All specimens were 
collected by a professional nurse. Cotton tipped swabs were used to sample the rectum of 
neonates. Three swabs were collected from each neonate and the swabs were then placed into 
10 ml sterile white screw capped tubes (Whitehead Scientific, Cape Town) and transported to 
the Infection Prevention and Control Laboratory on the premises. Each neonate was allocated 
a unique ‘R’ number given by the laboratory (Appendix B, Table 2).  
 
 
3.4. LABORATORY INVESTIGATIONS 
 
3.4.1. Bacterial Isolation and Detection of Carbapenemase producing  
          Enterobacteriaceae 
 
The 3 rectal swab specimens were used to inoculate each of the following media: 
 MacConkey agar (Oxoid, United Kingdom) for the isolation of Gram-negative bacilli 
(preparation as per Appendix C, 1.1).  
 Brilliance™ CRE agar (Oxoid, United Kingdom) for the detection of carbapenem-
resistant Gram-negative bacilli. 
 ChromID® CARBA agar plates (Biomerieux, France) for the detection of carbapenemase 
producing Gram-negative bacteria. 
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A four-way streak method was used to inoculate the plates to obtain single colonies (Shankel 
and Arnold, 1968). The plates were incubated at 37 °C, aerobically for 24 h. 
 
 
The plates were then read and an initial phenotypic assessment was made based on variation 
in colour (Table 1), from both the chromogenic agar plates, and based on lactose fermentation 
(yellow colonies) from the MacConkey plates. 
 
 
Based on the different morphologies colonies were picked off each of the MacConkey agar, 
Brilliance™ CRE and ChromID® CARBA agar plates. The selected colonies were plated out 
onto blood agar plates (preparation as per Appendix C, 1.4) to ensure purity.  These plates 
were then incubated at 37 °C for 24 h. A 0.5 McFarland standard was prepared by adding a 
single colony from the purity plate into 5 ml of distilled water. This was vortexed for 10-15 
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Table 1: Colour of Enterobacteriaceae Colonies on MacConkey and Chromogenic Agar 
        





K. pneumoniae Lactose-fermenters Blue Green-blue 
Enterobacter spp. Lactose-fermenters Blue - 
E. coli Lactose-fermenters Pink Orange-red 
Citrobacter spp. Weak Lactose-fermenters Blue - 
Serratia spp. Weak lactose-fermenter Blue - 
Proteus mirabilis Non-lactose fermenter - - 
 
 
The controls used throughout this study were: E. coli ATCC 25922 (negative control); and K. 
pneumoniae POZ KPC-3, K. pneumoniae DIH VIM-1, K. pneumoniae CHE GES-5, K. 




3.4.2. Identification of Gram-negative Bacilli  
 
Identification of each isolate was performed using the API 20E (Biomerieux, France) 
according to the instruction manual. The standardised bacterial suspension (equivalent to a 
0.5 MacFarland) was used for inoculation of the API 20E strips. Results were interpreted 
according to instruction manual (refer to Appendix D, Table 3a and 3b). These were 
incubated at 37 °C for 24 h.  
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3.4.3. Kirby-Bauer Disc Diffusion Susceptibility Test  
 
The standardised inoculums were seeded onto Mueller-Hinton agar (MHA) (Oxoid, United 
Kingdom), (preparation as per Appendix C, 1.2) using a cotton swab. The susceptibility test 
was performed using the Kirby-Bauer disc diffusion technique using the following antibiotic  
impregnated discs: ertapenem (10 µg), imipenem (10 µg), meropenem (10 µg), doripenem 
(10 µg), cefotaxime (30 µg), cefoxitin (30 µg), ceftazidime (30 µg), gentamicin (10 µg), 
ciprofloxacin (5 µg), nalidixic acid (30 µg), and chloramphenicol (30 µg) (Oxoid, United 
Kingdom). The susceptibility plates were incubated at 37 °C for 24 h. The diameter of the 
inhibition zones were measured and compared to the European Committee on Antimicrobial 
Susceptibility Testing (EUCAST) guidelines (2013).  
 
 
3.4.4. Storage of Isolates 
 
All isolates were stored for future testing. The colonies of a 24 h culture were picked off and 
added to cryovials containing 500 µl storage media with glass beads (preparation as per 
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3.5. PHENOTYPIC DETECTION OF CARBAPENEMASE PRODUCING 
ENTEROBACTERIACEAE 
 
3.5.1. Modified Hodge Test (MHT) 
 
The MHT was prepared according to the Clinical and Laboratory Standards Institute (CLSI) 
recommendations (2012). A single colony of E .coli ATCC 25922 was added into 5 ml of 
Mueller-Hinton broth (MHB) (preparation as per Appendix C, 1.3) and standardised to a 0.5 
McFarland. This inoculum was spread onto a MHA plate using a cotton swab and dried for 5 
min. Antibiotic discs (10 µg) for meropenem, imipenem, doripenem and ertapenem were 
placed at equal distances on the lawn 2 cm from the edge of the plate. The test isolate was 
streaked in a straight line from the edge of the discs to the centre of the plate (as shown in 
Fig. 5). These plates were incubated at 37 °C for 24 h.  
 
 
                         
                     Fig. 5: Image of the Modified Hodge Test 
 
Clover-leaf indent 
E. coli ATCC 25922 lawn 
Carbapenem discs 
Test isolate 
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A clover leaf-type indentation at the intersection of the test isolate and E.coli ATCC 25922, 
within the zone of inhibition of the carbapenem susceptibility disc, should appear after 
incubation. Results were interpreted according to CLSI recommendations (2012) as follows: 
if there was no distortion of the inhibition zone around the disc then the test was negative, if 
there was distortion of the E. coli ATCC 25922 inhibition zone around the disc then the test 
was positive, and the test was indeterminate if the inhibition of E. coli ATCC 25922 growth 
around the streaked test isolates are evident by a clear area. A positive MHT was an 
indication that the test isolates produced carbapenemases.         
 
 
3.5.2. Amoxycillin-Clavulanate Double Disc Synergy Test 
 
A 0.5 McFarland standard was prepared for each test isolate. The standardised suspensions 
were spread onto MHA plates and left to dry for 5 min. Amoxycillin-clavulanate (AMC) 
discs were placed at the centre of the lawn, with meropenem, imipenem, doripenem and 
ertapenem discs (10 µg) placed at 2 cm away from the inhibitor disc (AMC), (as shown in 
Fig. 6). The plates were incubated at 37 °C for 24 h. This method was performed using an in-
house technique.  
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Fig. 6: Amoxycillin-clavulanate inhibitor test  
 
 




3.6.1.1. Preparation of antibiotic stock 
 
MICs for the 4 carbapenems were performed on all K. pneumoniae and E. cloacae isolates. 
The MIC breakpoint of the specific antibiotics used is shown in Table 2. The range of the 
antibiotic concentration tested was 4 dilutions above and 4 below the known breakpoint for 
resistance. These tests were performed in triplicate. The appropriate amount of antibiotic 
powder was weighed out using the calculations shown in appendix E (1.1). The antibiotic 
stocks were prepared as follows: 0.010 g of ertapenem dissolved in 10 ml distilled water, 
0.013 g of doripenem dissolved in 10 ml distilled water, 0.027 g of imipenem dissolved in 10 
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antibiotic stock solutions were filter sterilised, aliquoted into cryovials and stored at -20 °C 
until needed.     
 
 
3.6.1.2. Preparation of bacterial suspension 
 
A 0.5 McFarland standard was prepared as described in 3.4.2. 
 
 
3.6.1.3. Minimum Inhibitory Concentration using Microbroth-dilution method 
 
MICs were performed in a 96 well microtitre plate. Two hundred microlitres of antibiotic 
stock was dispensed into well 1 only and 100 µl was dispensed into well 10. One hundred 
microlitres of MHB was then dispensed into wells 2 to 12. Two-fold dilutions were 
performed by transferring 100µl from well 1 to well 2, consecutively until well 9 (the final 
100µl from well 9 was discarded). After dilutions were made, 100µl of bacterial suspension 
was dispensed into wells 1-9 and well 12. Well 10 was used as the antibiotic control, well 11 
was used as the broth control and well 12 was used as the bacterial growth control. The plates 
were incubated at 37 ºC for 18-24 h. MIC results were then read as the lowest concentration 
of antimicrobial agent that completely inhibited the growth of the organisms in micro-dilution 
wells. Results were interpreted according to EUCAST and CLSI breakpoints as updated in 
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3.6.2. E-Test 
The stored isolates were revived. A bacterial suspension was prepared and standardised to a 
0.5 McFarland. This was streaked out onto blood agar plates and incubated at 37 °C for 24 h. 
The E-tests were performed for imipenem, ertapenem, meropenem and doripenem 
(Biomerieux, France). The bacterial inoculums were spread onto MHA plates and dried for 5 
min. The E-test strips were placed on the lawns using sterile forceps and the plates were 
incubated for 24 h at 37 ᵒC. An elliptical zone of inhibition will form and the MICs are read 
directly from the graduated E-test strips at the point of intersection of the inhibition zone with 
the strip. Results were interpreted according to the EUCAST and CLSI breakpoints (shown in 
table 2a and 2b).  
 
 
3.6.3. VITEK® 2 Automated System 
 
Antimicrobial susceptibility testing using VITEK® 2 (Biomerieux, France) was performed 
by the National Health Laboratory Services (NHLS) at Mahatma Gandhi Memorial Hospital, 
KwaZulu-Natal, South Africa according to the instruction manual. Twenty-four hour cultures 
were prepared as previously described. These cultures were standardised according to a 0.5 
McFarland standard. The VITEK® 2 automated system (Biomerieux, France) was used to 
determine the MICs of ertapenem, meropenem and imipenem using the AST-N255 
susceptibility cards (Biomerieux, France). Doripenem was not available on test system. The 
results were interpreted according to the EUCAST and CLSI breakpoints as updated in 2013 
and 2012, .respectively (shown in table 2a and 2b). Further interpretation was performed by 
the VITEK® 2 automated system with the use of the Advanced Expert System (AES). The 
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AES is a database that comprises of information pertaining to the specific organism and its 
specific MIC results based on previous findings.   
 
 
Table 2a: MIC interpretive standards for Enterobacteriaceae according to EUCAST 
guidelines  
   
Antimicrobial agent 
MIC breakpoint (mg/L) 
Susceptible ≤ Resistant > 
Ertapenem 0.5 1 
Doripenem 1 4 
Imipenem 2 8 
Meropenem 2 8 
   
   Table 2b: MIC interpretive standards for Enterobacteriaceae according to CLSI 
guidelines  
   
Antimicrobial agent 
MIC breakpoint (mg/L) 
Susceptible ≤ Resistant ≥ 
Ertapenem 0.5 2 
Doripenem 1 4 
Imipenem 1 4 
Meropenem 1 4 
 
 
3.7. GENE DETECTION FOR CARBAPENEMASES 
 
3.7.1. DNA extraction 
 
The isolates that had MICs ranging from intermediate to resistant were used. These were 
grown on MacConkey agar and incubated for 18-24 h at 37 °C. Crude DNA was extracted 
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using a boiling method. This was done by picking off 5 to 6 pure colonies from different 
sections of the plate. The colonies were inoculated in 400 µl of 1x Tris-EDTA (TE) buffer 
(preparation as per Appendix F, 1.1.) and vortexed for 10-15 seconds or until suspension is 
emulsified. This was placed on the heating block for 25 min at 95 °C. After which it was 
centrifuged for 3 min at 12 000 rpm. A 1:10 dilution of the supernatant was prepared by 
adding 2 µl of the supernatant into 8 µl of PCR-grade water (Roche, Switzerland).      
 
 
3.7.2. Multiplex Real-Time PCR 
 
Multiplex real-time PCR was performed using the Lightcycler® 480 II real-time instrument 
(Roche, Switzerland). The TIB Mobiol PCR kits (Roche, Switzerland) were used to 
determine the presence or absence of the carbapenemase genes (refer to table 3). The 
mastermix that was used was the Lightcycler® 480 Probes Master kit (Roche, Switzerland). 
These kits were used as per instruction manuals. Briefly, 2 multiplex real-time PCR reactions 
were set up. The first PCR targeted the blaKPC, blaNDM-1/2 and blaOXA-48, for which the 
mastermix was prepared as described in Appendix F, table 4a. The second PCR targeted 
blaVIM, blaIMP and blaGES, for which the mastermix was prepared as described in Appendix F, 
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Table 3: Lightmix Primer/ Probe Kits for the Detection of Genes encoding 
Carbapenemases  
  Carbapenemase genes TIB Mobiol PCR Lightmix kits 
blaKPC Lightmix Modular KPC (ESBL) 
blaIMP Lightmix Modular IMP (ESBL) 
blaOXA-48 Lightmix Modular OXA-48 (ESBL) 
blaNDM-1 Lightmix Modular NDM-1/2 (ESBL) 
blaVIM Lightmix Modular VIM (ESBL) 
blaGES Lightmix Modular GES (ESBL) 
Internal control Lightmix Modular PhHV internal control 
 
A Lightmix Modular PhHV internal control (Roche, Switzerland) was used throughout the 
run and produced positive results for all isolates. Positive kit controls for KPC, NDM-1, GES, 
IMP, VIM and OXA-48  were used in parallel with each run performed. These controls were 
run to ensure that valid results are produced.  
 
 
The cycle conditions that were used are shown below (Appendix F, Table 4). 
 
 
Results were interepreted as follows: If the amplified product produced a crossing point (CP) 
value of less than 37  (between cycles 10-40) in the relevent channels then the result is taken 
as positive. If the amplification curve occurs from cycle 41-45 then the result is recorded as 
low positive. If no amplification curves are produced or if it is amplified beyond the 46
th
 
cycle and has a CP value > 45 then this is taken as a negative result. If a diluted sample is run 
and an amplification curve is produced after the 46
th
 cycle, this may lead to a low positive 
result.   





4.1. GRAM-NEGATIVE BACILLI ISOLATED 
 
There was no growth from the rectal swabs of 8 neonates. A total of 241 Enterobacteriaceae 
were isolated from the remaining 22 neonates. One or more isolates per species were 
identified per neonate. The 3 most prevalent species isolated were K. pneumoniae (94), E. 
coli (80), and E. cloacae (41), (Table 4). Of these, 97 grew on the Brilliance™ CRE agar: K. 
pneumonia (n=38), E. cloacae (n=22), E. aerogenes (n=2), E. coli (n=34), and P. mirabilis 
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R1    
R2       
R3    
R4    
R6          
R8    
R9       
R11    
R12    
R14       
R16          
R17                
R18             
R19          
R20       
R21          
R23             
R24       
R25       
R28             
R29          
R30    
Total no.
of isolates
94 41 2 80 15 3 5 1
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4.2. KIRBY-BAUER SUSCEPTIBILITY TEST 
 
Of the Enterobacteriaceae that grew on the MacConkey agar plates, only K. pneumoniae and 
E. cloacae were resistant to carbapenems based on the Kirby-Bauer susceptibility testing 




Based on the EUCAST criteria (2013), 9 K. pneumoniae isolates were resistant to 
carbapenems. These isolates had zone sizes of ≤22 mm for ertapenem, and ≤18 mm for 
doripenem, and ≤16 mm for imipenem and meropenem (Table 6). Fifty-eight K. pneumoniae 
isolates were resistant to all the cephalosporins and ciprofloxacin. Sixteen E. cloacae isolates 
were resistant to the carbapenems. Seven of these also grew on Brilliance™ CRE agar. All E. 
cloacae isolates were resistant to the cephalosporins, ciprofloxacin, chloramphenicol, 
nalidixic acid and gentamycin (Table 6).





Brilliance™ CRE agar 
(Carbapenem-resistant) 
K. pneumoniae 94 38
E. cloacae 41 22
E. aerogenes 2 2
E. coli 80 34
P. mirabilis 15 1
S. liquefaciens 3 0
S. marcescens 5 0
M. morganii 1 0
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Table 6: Kirby-Bauer Susceptibility Patterns for Enterobacteriaceae using EUCAST Criteria
 
This table represents the organisms identified in this study and the specific susceptibility patterns of these organisms for several antibiotics. The figures in green 
 represent the intermediate diameter; figures in red represent the resistant diameter. ERT: ertapenem, IMP: imipenem, MEM: meropenem, DOR: doripenem, CTX:  
 cefotaxime, FOX: cefoxitin, CAZ: ceftazidime, C: gentamycin, CIP: ciprofloxacin, CN: chloramphenicol. * NA: naladixic acid (present in CLSI guidelines only). 
ERT IMP MEM DOR CTX FOX CAZ C CIP *NA CN
K. pneumoniae (2) ≥25 ≥22 ≥22 ≥24 ≥20 ≤19 ≥21 ≤17 ≥22 ≥19 ≥17
K. pneumoniae (51) ≥25 ≥22 ≥22 ≥24 ≤17 ≤19 ≤17 ≤17 ≤19 ≤13 ≥17
K. pneumoniae (24) ≥25 ≥22 ≥22 ≥24 ≥20 ≤19 ≥21 ≤17 ≥22 ≥19 ≤14
K. pneumoniae (8) ≥25 17-21 ≥22 ≥24 ≥20 ≤19 18-20 ≤17 ≤19 ≤13 ≤14
K. pneumoniae (2) ≥25 ≥22 ≤16 ≥24 ≤17 ≤19 ≥21 ≤17 ≥22 14-18 ≥17
K. pneumoniae (7) ≤22 ≥22 ≥22 ≤18 ≤17 ≤19 ≤17 ≤17 ≤19 ≤13 ≤14
E. coli (18) ≥25 ≥22 ≥22 ≥24 ≥20 ≤19 ≥21 ≤17 ≥22 ≥19 ≥17
E. coli (56) ≥25 ≥22 ≥22 ≥24 ≤17 ≤19 ≤17 ≤17 ≤19 ≤13 ≥17
E. coli (3) ≥25 ≥22 17-21 ≥24 ≤17 ≤19 ≤17 ≤17 ≤19 ≤13 ≥17
E. coli (2) 21-24 ≥22 ≥22 ≥24 ≤17 ≤19 ≤17 ≤17 ≤19 ≤13 ≤14
E. coli (1) ≥25 17-21 ≥22 ≥24 18-19 ≤19 ≥21 ≤17 ≥22 ≥19 ≥17
E. cloacae (17) ≥25 ≥22 ≥22 ≥24 ≤17 ≤19 ≤17 ≤17 ≤19 ≤13 ≤14
E. cloacae (16) 21-24 ≤16 ≤16 ≤18 ≤17 ≤19 ≤17 ≤17 ≤19 ≤13 ≤14
E. cloacae (8) 21-24 ≥22 ≥22 ≥24 ≤17 ≤19 ≤17 ≤17 ≤19 ≤13 ≤14
E. aerogenes (1) ≥25 ≥22 ≥22 ≥24 ≥20 ≤19 ≥21 ≤17 ≥22 ≥19 ≥17
E. aerogenes (1) ≥25 ≥22 ≥22 ≥24 ≥20 ≤19 ≥21 ≤17 ≥22 ≥19 ≥17
P. mirabilis (8) ≥25 ≥22 ≥22 ≥24 ≥20 ≤19 ≥21 ≤17 ≥22 ≥19 ≤14
P. mirabilis (5) ≥25 ≥22 ≥22 ≥24 ≤17 ≤19 ≤17 ≤17 ≤19 ≤13 13-16
P. mirabilis (1) ≥25 20-22 ≥22 19-23 ≥20 ≤19 ≥21 ≤17 ≥22 ≥19 13-16
P. mirabilis (1) ≥25 ≥22 ≥22 19-23 ≥20 ≤19 ≥21 ≤17 ≤19 ≤13 ≤14
S. liquefaciens (1) ≥25 ≥22 ≥22 ≥23 ≥20 ≤19 ≥21 ≤17 ≤19 ≤13 ≥17
S. liquefaciens (2) ≥25 ≥22 ≥22 ≥23 ≥20 ≤19 ≥21 ≤17 ≥22 ≥19 ≥17
S. marcescens (5) ≥25 ≥22 ≥22 ≥23 ≥20 ≤19 ≥21 ≤17 ≥22 ≥19 ≥17
M. morganii (1) ≥25 17-21 ≥22 ≥24 ≥20 ≤19 ≥21 ≤17 ≤19 ≥19 ≤14
*NA: nalidixic acid (EUCAST guidelines absent for NA, therefore CLSI guidelines used)
Zone of inhibition (mm)
Isolates (n)
This Table represents the organisms identified in this study and the specific susceptibility patterns of these organisms for several antibiotics. The figures in green represent
the intermediate diameter; figures in red represent the resistant diameter. ERT: ertapenem, IMP: imipenem, MEM: meropenem, DOR: doripenem, CTX: cefotaxime, 
FOX: cefoxitin, CAZ: ceftazidime, C: gentamycin, CIP: ciprofloxacin, CN: chloramphenicol. 
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When comparing the susceptibility criteria of the CLSI (2012) and the EUCAST (2013) 
guidelines, differences were noted (Tables 7a and 7b). Thirty-eight K. pneumoniae isolates 
grew on Brilliance™ CRE agar. Based on the CLSI criteria, 3 were resistant and 3 were 
intermediate. However, based on the EUCAST criteria, 6 were resistant and 6 were 
intermediate as per the Kirby-Bauer susceptibility testing. Twenty-two E. cloacae isolates 
grew on Brilliance™ CRE agar. Based on the CLSI criteria, 7 were resistant, and based on 
the EUCAST criteria 9 were resistant as per the Kirby- Bauer susceptibility testing.  
 
 
Table 7a: Comparison of the Kirby-Bauer Susceptibility Patterns based on the CLSI  




The comparison of the CLSI and EUCAST criteria for the susceptibilities for organisms that 
grew from MacConkey agar plates, but not on Brilliance™ CRE is shown in Table 7b. Fifty- 
six K. pneumoniae and 19 E. cloacae isolates did not grow on the Brilliance™ CRE agar. 
However, 7 E. cloacae isolates were resistant to the carbapenems based on the EUCAST 
criteria, and 4 were resistant based on the CLSI criteria. Among the K. pneumoniae isolates, 2 
and 3 isolates were resistant based on the CLSI and EUCAST criteria, respectively. 
  
R I S R I S
K. pneumoniae 38 3 3 32 6 6 26
E. cloacae 22 7 7 8 9 6 7
Kirby-Bauer susceptibility  
CLSI EUCAST
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Table 7b: Comparison of the Kirby-Bauer Susceptibility Patterns based on the CLSI  





4.3. MODIFIED HODGE TEST (MHT) AND AMOXYCILLIN-CLAVULANATE 
(AMC) DOUBLE DISC SYNERGY TEST 
 
Seventy nine percent (30/38) of the K. pneumoniae isolates that grew on Brilliance™ CRE 
and 64% (36/56) that did not grow on the Brilliance™ CRE had a positive MHT result (p = 
012), (Table 8a). Among the E. cloacae isolates, 91% (20/22) that grew on the Brilliance™ 
CRE and 79% (15/19) that were inhibited by the Brilliance™ CRE produced a positive MHT 








R I S R I S
K. pneumoniae 56 2 1 53 3 2 51
E. cloacae 19 4 4 11 7 2 10
Kirby-Bauer susceptibility  
EUCASTCLSI
Isolates that were 
inhibited by   
Brilliance™ CRE 
Isolates
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Table 8a: MHT Results for Klebsiella pneumoniae (n=94) Stratified by Growth on 




Table 8b: MHT Results for Enterobacter cloacae (n=41) Stratified by Growth on 







Brilliance™ CRE Positive Negative
Growth 30 8
Growth Inhibited 36 20
Modified Hodge Test
Brilliance™ CRE Positive Negative
Growth 20 2
Growth Inhibited 15 4
Modified Hodge Test
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Fig. 7: MHT test results for (A) E. cloacae harbouring carbapenemase (positive control) and 
(B) positive result for test isolate K. pneumoniae KP37.   
 
 
Among the K. pneumoniae isolates, a positive AMC double disc synergy test result was 
significantly higher amongst isolates that grew on the Brilliance™ CRE agar than those that 
did not [79% (30/38) vs 57% (32/56)] (p = 0.02). For E. cloacae, there was no significant 
difference [55% (12/22) vs 32% (6/19)] (p=0.14), (Tables 9a and 9b). 
 
 
Table 9a: AMC Double Disc Synergy Test for Klebsiella pneumoniae (n=94) Stratified 
by the Growth on Brilliance™ CRE Agar 
 
 
Brilliance™ CRE Positive Negative
Growth 30 8
Growth Inhibited 32 24
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Table 9b: AMC Double Disc Synergy Test for Enterobacter cloacae (n=41) Stratified by 




                  
Fig. 8: Positive result for AMC double disc synergy test for test isolate K. pneumoniae R21 
 
 
4.4. MINIMUM-INHIBITORY CONCENTRATION (MIC)  
 
According to the MIC results from the 3 different techniques (microbroth-dilution, E-test and 
VITEK® 2) performed, the Brilliance™ CRE agar appeared to support the growth of K. 
pneumoniae and E. cloacae isolates that produced both resistant and susceptible carbapenem 
MICs. When comparing these results to the MIC results of the K. pneumoniae and E. cloacae 
Brilliance™ CRE Positive Negative
Growth 12 10
Growth Inhibited 6 13
AMC Double Disc Synergy Test
Augmentation of 
inhibitory zone 
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isolates that grew on MacConkey agar, some isolates had resistant MICs for the 
carbapenems, but these isolates did not grow on the Brilliance™ CRE agar (Table 10).  
 
 
When comparing the CLSI and EUCAST results for the K. pneumoniae isolates that grew on 
the Brilliance™ CRE agar, it was observed that the difference was not as significant. The 
microbroth-dilution MICs showed that none of the K. pneumoniae isolates were resistant 
based on the EUCAST and CLSI breakpoint criteria’s. However, only 1 K. pneumoniae had 
an intermediate MIC based on the CLSI breakpoints but this was not evident based on the 
EUCAST breakpoints. The E-test results showed that 1 K. pneumoniae isolate had a resistant 
MIC using EUCAST breakpoints and 1 isolate had an intermediate MIC using this 
breakpoint. However, the latter was not evident based on the CLSI breakpoints, since there 
was no K. pneumoniae isolate that had resistant or intermediate results.   
 
 
When comparing the EUCAST and CLSI breakpoints for E. cloacae, there appeared to be a 
slight difference in the resistance patterns for the carbapenems. Most of the isolates had 
intermediate MICs based on the EUCAST breakpoints, but these isolates were resistant based 
on the CLSI breakpoints. It was observed that the E. cloacae isolates that grew from 
Brilliance™ CRE agar differed significantly when comparing the EUCAST and CLSI 
breakpoint criteria for all 3 MIC methods. The microbroth-dilution results showed that only 2 
E. cloacae isolates had resistant MICs based on the EUCAST and CLSI breakpoints. 
However, 2 E. cloacae isolates also had intermediate MICs based on the EUCAST criteria 
but 8 were intermediate based on the CLSI criteria (Table 10). The E-test results for these 
organisms showed that 7 had resistant MICs based on the EUCAST breakpoints but 4 were 
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resistant based on the CLSI breakpoints. The VITEK® 2 results showed that 12 E. cloacae 
isolates were resistant based on both the EUCAST and CLSI breakpoint criteria. However, 5 
E. cloacae isolates that were intermediate based on the CLSI breakpoints were not resistant 
based on the EUCAST breakpoints (Table 10).  
 
 
Table 10: MIC determination for K. pneumoniae and E. cloacae grown from 







Microbroth-dilution E-Test VITEK® 2  
EUCAST CLSI EUCAST CLSI EUCAST CLSI 



































































0 0 38 0 1 37 1 1 36 0 0 38 1 0 37 1 0 37 
Enterobacter 
cloacae         
(n= 22) 
2 2 18 2 8 12 7 2 15 4 6 12 12 0 10 12 5 5 
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Table 11a to 11e show the MICs results for K. pneumoniae and E. cloacae from the 
techniques used. All figures in red represent the resistant MICs and those in green represent 
the intermediate MICs. Only two K. pneumoniae isolates had resistant MIC values from the 
microbroth-dilution method (Table 11a). Isolate KP5 had a resistant MIC value of 1 mg/L for 
ertapenem and KP37 had resistant MIC values of 4 mg/L for ertapenem, 4 mg/L for 
doripenem, 16 mg/L for meropenem and 8 mg/L for imipenem.  
 
 
Table 11a: MIC results from the Microbroth-Dilution Method for 94 K. pneumoniae test 




≤0.0625 0.125 0.25 0.5 1 2 4 8 16 32 64 ≥128 
ERT 85 4 3 0 1 0 1 0 0    
DOR   70 9 13 1 1 0 0 0 0  
MEM    89 1 3 0 0 1 0 0 0 
IMP    84 7 2 0 1 0 0 0 0 
 
 
Four E. cloacae isolates were resistant to the carbapenems from the microbroth-dilution 
(Table 11b). Isolates EC5 and EC6 had the similar results with an intermediate MIC value of 
4 mg/L for imipenem. Isolate EC9 had resistant MIC values of 2 mg/L for ertapenem and 
intermediate MIC values for imipenem (4 mg/L) and doripenem (2 mg/L). Isolate EC12 was 
resistant to ertapenem with a MIC value of 1 mg/L and an intermediate MIC value of 4 mg/L 
for imipenem and 2 mg/L for doripenem. Isolate EC21 produced intermediate results for 
meropenem with a MIC value of 4 mg/L, a resistant MIC value of 2 mg/L for ertapenem and 
4 mg/L for doripenem but was susceptible to imipenem.     
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Table 11b: MIC results from the Microbroth-Dilution Method for 41 E. cloacae test 




≤0.0625 0.125 0.25 0.5 1 2 4 8 16 32 64 ≥128 
ERT 27 3 3 5 1 2 0 0 0    
DOR   27 3 7 3 1 0 0 0 0  
MEM    31 7 2 1 0 0 0 0 0 
IMP    25 4 8 4 0 0 0 0 0 
 
 
Based on the E-test method, all K. pneumoniae isolates were susceptible with the exception 
of KP37 (Table 11c). The MIC values for the resistant isolate KP37 had a resistant MIC value 
of 6 mg/L for ertapenem, 6 mg/ L for doripenem and 8 mg/L for imipenem. Isolate KP5 and 
KP30 had an intermediate MIC value of 0.75 mg/L for ertapenem.  
 
 
Eight E. cloacae isolates were resistant to carbapenems from the E-tests (Table 11c). Isolates 
EC5 and EC6 had a resistant MIC value of 1.5 mg/L and 2 mg/L for ertapenem, respectively. 
Isolate EC9 had an intermediate MIC value of 0.75 mg/L for ertapenem and were susceptible 
to imipenem and doripenem. Isolate EC12 was resistant to ertapenem with a MIC value of 1 
mg/L and an intermediate MIC value of 3 mg/L for imipenem. Isolate EC21 was resistant to 
ertapenem and doripenem with a MIC of 3 mg/L and 4 mg/L, respectively, and an 
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ERT DOR IMP ERT DOR IMP
>32 0 0 0 0 0 0
24 0 0 0 0 0 0
16 0 0 0 0 0 0
12 0 0 0 0 0 0
8 0 0 1 0 0 0
6 1 1 0 0 0 0
4 0 0 0 0 1 0
3 0 0 0 1 0 2
2 0 0 2 3 0 6
1.5 0 0 0 3 1 4
1 0 1 0 1 0 3
0.75 2 0 1 6 0 0
0.5 2 3 0 5 5 4
0.38 3 0 3 2 3 4
0.25 15 1 9 4 6 9
0.19 10 8 22 2 4 9
0.125 6 10 21 3 5 0
0.094 0 21 2 3 5 0
0.064 0 0 0 1 6 0
0.047 2 11 8 0 5 0
0.032 9 8 20 0 0 0
0.023 9 0 0 0 0 0
0.016 7 30 5 7 0 0
0.012 20 0 0 0 0 0
0.008 8 0 0 0 0 0
K. pneumoniae (94) E. cloacae (41)
Antibiotics Antibiotics
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The VITEK® 2 AES showed that of the 94 K. pneumoniae strains isolated, 39 were assumed 
to harbour the OXA enzyme, 37 were ESBL-positive strains, and 18 harboured both ESBLs 
and were impermeable. Results from the VITEK® 2 showed that only 2 K. pneumoniae 
isolates were resistant (Table 11d). Isolate KP29 had a resistant MIC of 4 mg/L for 
ertapenem, but produced susceptible MIC values of 1 mg/L for both meropenem and 
imipenem. This isolate was assumed to be positive for OXA enzyme according to the AES 
interpretation. The second isolate that was resistant was the KP37. This isolate had a resistant 
MIC value of 8 mg/L for ertapenem and susceptible MIC values (2 mg/L) for both 
meropenem and imipenem. According to the AES interpretation, isolate KP37 was 
inconsistent with the results from the database. All other K. pneumoniae isolates were 
completely susceptible to meropenem, ertapenem and imipenem.  
 
 
Table 11d: MIC results from the VITEK® 2 method for 94 K. pneumoniae test isolates 
based on the EUCAST breakpoints 
 
Antibiotics 
 Dilutions (mg/L)  
≤0.25 0.5 1 2 4 8 16 32 ≥64 
ERT  92 0 0 1 1 0 0 0 
MEM 92 0 1 1 0 0 0 0  
IMP 84 5 4 1 0 0 0 0  
 
 
According to the VITEK® 2 AES interpretation, of the 41 E. cloacae isolates, 23 harboured 
MBLs and/ or KPC, 6 were ESBL-positive, and 12 harboured both the ESBLs and AmpC. 
The VITEK® 2 results showed that 15 E. cloacae isolates had resistant MICs. All 15 isolates 
were only resistant to ertapenem (Table 11e). Fourteen of which had an MIC value of 4 mg/L 
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and 1 (EC9) had an MIC value ≥8 mg/L. All resistant isolates were assumed to carry the 
MBL or KPC enzymes according to the AES.        
 
 
Table 11e: MIC results from the VITEK® 2 method for 41 E. cloacae test isolates based 
on the EUCAST breakpoints  
 
Antibiotics 
 Dilutions (mg/L)  
≤0.25 0.5 1 2 4 8 16 32 ≥64 
ERT  22 4 0 14 1 0 0 0 
MEM 21 1 16 3 0 0 0 0  




4.5. GENE DETECTION: MULTIPLEX REAL-TIME PCR 
 
Multiplex real-time PCR were performed on all K. pneumoniae and E. cloacae isolates that 
were either intermediate or resistant to the carbapenems from the Kirby-Bauer susceptibilty 
tests, Microbroth-dilution, E-test and VITEK® 2. A total of 41 test isolates were run, from 
which only 1 K. pneumoniae isolate (KP37) was positive for the blaOXA-48 with a CP value of 
20.70 (as shown in Fig. 9). All other isolates from this study were negative for all 6 
carbapenemases and their variants (Appendix F, 2).  
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Fig. 9: Amplification curves from Real-time PCR results for blaOXA-48: Green and Red amplification curves: 
OXA-48 positive kit control. Orange amplification curve: NICDs in-house blaOXA-48 positive control (K. 
pneumoniae NCTC 13442). Pink amplification curve: test isolate KP37. Flat lines: represent all isolates that 


















In the past 10 years, the emergence of CRE has spread rapidly worldwide (Drew et al., 2013). 
The primary mechanisms of carbapenem resistance includes: the development of resistance 
due to the production of carbapenemases, and impermeability in combination with AmpC or 
other ESBL activity. CRE poses a serious threat in healthcare settings by causing infections 
that are virtually untreatable. Carbapenem-producing Enterobacteriaceae (CPE) have been 
implicated in the transmission of resistance genes to various pathogens within the hospital 
setting, as well as in large mono- or multi-clonal hospital outbreaks (Vrioni et al., 2012). The 
need for the rapid detection of CPE from colonised patients is imperative. This will assist in 
the timeous implementation of infection control policies, in an attempt to prevent further 
dissemination of such resistant pathogens within the hospital setting (Bracco et al., 2013; 
Vrioni et al., 2012).  
 
 
Rectal swabs collected from neonates at the KEH VIII hospital were inoculated directly onto 
the Brilliance™ CRE and ChromID® CARBA agar to evaluate these commercial screening 
methods for CRE. The Brilliance™ CRE agar plates are used for the presumptive detection of 
carbapenem-resistant organisms (regardless of mechanism of resistance), and the ChromID® 
CARBA agar plates are used for the presumptive detection of carbapenemase-producing 
organisms. The  ChromID® CARBA agar are supplemented with specific ingredients that 
allow for the inhibition of Gram-positive and non-carbapenemase producers, whilst the 
Brilliance™ CRE agar are supplemented with ingredients that assist in inhibiting Gram-
positive organisms only (Vrioni et al., 2012). Both the chromogenic agar constitutes of a 
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combination of peptones, carbohydrates, several antibiotics and a mixture of chromogenic 
substrates. The antibiotics favour the selective growth of CREs and CPEs (on the 
Brilliance™ CRE and ChromID® CARBA agar, respectively) and the chromogenic 
substrates are indicators of the activity of specific metabolic enzymes that may be used to 
differentiate Enterobacteriaceae.    
 
 
The Brilliance™ CRE agar contains a modified carbapenem that is compatible with 
EUCAST and CLSI criteria for the detection of resistance. The organisms that grow on this 
agar should therefore be resistant to the carbapenems. In this study, a total of 38 K. 
pneumoniae isolates grew on Brilliance™ CRE agar. However, only 6 were resistant to 
carbapenems based on the Kirby-Bauer susceptibility test and 2 were resistant as per all MIC 
tests performed.  
 
 
In comparison, the ChromID® CARBA agar did not appear to support the growth of any 
organisms. Our results are in contrast to the study by Vrioni et al. (2012), who showed that 
73 rectal swab specimens were collected, from which 89 isolates grew as greenish blue 
colonies on ChromID® CARBA agar and were presumed to be CPE. The molecular tests 
performed on the variety of organisms that grew on the chromogenic media were identified as 
follows: 54 were KPC-positive K. pneumoniae, 25 were VIM-positive K. pneumoniae and 6 
were KPC-positive E. aerogenes strains (Vrioni et al., 2012). The study showed that the 
ChromID® CARBA agar displayed 97% specificity for the detection of CPE. However, the 
study was performed in an area where the prevalence of blaKPC and blaVIM producing isolates 
was high, as compared to our study where CPE production amongst Enterobacteriaceae is 
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uncommon. Since all control strains grew as expected, the results suggested that none of the 
isolates were carbapenemase producers. The production of carbapenemases are infrequent in 
South Africa. This was evident from the results reported by NICD-NHLS in 2014, where 
only a total of 34 Enterobacteriaceae were screened for carbapenemase production, of which 
only 22 were detected as carbapenemase-positive. Ten isolates were positive for NDM, of 
which only 6 were from a private hospital in KwaZulu-Natal and 4 from public hospitals in 
the Free-State and Western Cape. Seven isolates harboured the OXA-48 enzyme, of which 6 
identified in Gauteng and KwaZulu-Natal and 1 was from a public hospital in Gauteng. Five 
VIM-positive isolates were detected from public hospitals in Gauteng. 
 
 
When comparing the growth of carbapenem-resistant isolates on the Brilliance™ CRE agar 
to MacConkey agar, it appeared that some isolates that grew on MacConkey agar were 
resistant to the carbapenems but did not grow on the Brilliance™ CRE agar. In a study by 
Wilkinson et al. (2012), when comparing ChromID® CARBA agar and Brilliance™ CRE 
agar it was observed that the ChromID® CARBA agar was highly sensitive in comparison to 
the Brilliance™ CRE agar in terms of CPE detection. According to Bracco et al. (2013), the 
Brilliance™ CRE agar was able to support the growth of various carbapenem-resistant and 
carbapenemase-producing isolates, particularly strains that harboured the KPC, VIM and IMP 
β-lactamases. However, these isolates were previously characterised on a molecular level 
before growing them on the chromogenic agar, therefore they were known carbapenemase 
producers (Bracco et al., 2013).  
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The results from our study showed that both the chromogenic agars were unreliable for the 
detection of CREs and CPEs. It may appear that the Brilliance™ CRE agar does allow easy 
differentiation of bacterial isolates based on the colour of each species. However, K. 
pneumoniae and Enterobacter spp. both grew as dark blue, light blue and brown colonies 
which made it difficult to differentiate one organism from the other. It may be postulated that 
the chromogenic substrates are not specific for each of these species. According to a study by 
Day et al. (2013), 153 Enterobacteriaceae isolates grew on Brilliance™ CRE but did not 
produce carbapenemases and were not resistant to meropenem. However, 55% of these 
isolates produced other ESBLs and 12% produced AmpC β-lactamases (Day et al., 2013). It 
was concluded that the presence of other ESBL producers as well as AmpC non-
carbapenemase producers may grow on Brilliance™ CRE agar. This supports our results 
where, despite the 38 K. pneumoniae and 22 E. cloacae isolates that grew on Brilliance™ 




Carbapenem antimicrobial agents have been used extensively in clinical settings as a result of 
the emergence and spread of MDR strains that produce ESBLs (Drew et al., 2013). In our 
study, 9 K. pneumoniae isolates were resistant to carbapenems based on the Kirby-Bauer 
susceptibility test: 7 to ertapenem and doripenem, and 2 were resistant to meropenem only 
(Table 6). The latter isolates were also resistant to the cephalosporins, ciprofloxacin, 
chloramphenicol and naladixic acid. These results are comparable to a study performed by 
Day et al. (2013), where 37 Enterobacteriaceae harbouring the blaNDM-1 were resistant to 
ertapenem, cefotaxime, ciprofloxacin and other drugs used in the study, but were susceptible 
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to meropenem and imipenem. However, doripenem could not be compared since it was not 
used for susceptibility testing in the latter study.   
 
 
Sixteen E. cloacae isolates in this study were resistant to meropenem, imipenem and 
doripenem; and 8 were intermediate resistance to ertapenem (Table 6). The current study was 
similar to a study performed by Drew et al. (2013), who reported on the isolation of 7 
carbapenemase producing Klebsiella sp., and 11 Enterobacteriaceae producing AmpC/ 
ESBL in combination with decreased permeability to the outer membrane. The 
carbapenemase producers were more resistant to cephalosporins and carbapenems in 
comparison to those that harboured the AmpC/ ESBL and had decreased permeability as a 
resistance mechanism (Drew et al., 2013). Drew et al. (2013) also showed that the prevalence 
of carbapenemases was limited in comparison to the production of the AmpC/ ESBL activity 
and impermeability mechanisms by Enterobacteriaceae. This was evident since, 71% of the 
patients that harboured 76% Enterobacter spp., 12% Klebsiella spp., and 12% Serratia spp., 
were resistant to carbapenems due to the presence of AmpC/ ESBL activity and 
impermeability whereas only 29% Klebsiella sp. harboured blaNDM and blaKPC 
carbapenemases (Drew et al., 2013).  
 
 
The susceptibility profiles of K. pneumoniae and E. cloacae isolates, when comparing the 
EUCAST with CLSI guidelines, did not always concur. According to the CLSI guidelines, a 
zone diameter of ≤18 mm for ertapenem, and ≤22 mm for meropenem, imipenem and 
doripenem, should be used to classify an organism as being resistant. However, according to 
the EUCAST guidelines a zone of inhibition diameter of ≤22 mm for ertapenem, ≤16 mm for 
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meropenem and imipenem, and ≤18 mm for doripenem, is classified as resistant. Therefore, 
some isolates in this study that were intermediate or even susceptible based on the CLSI 
criteria, were classified as resistant according to the EUCAST guidelines. Due to such 
differences in the inhibitory zone sizes when comparing the EUCAST and CLSI criteria for 
susceptibility testing, the detection of carbapenem resistant isolates could go unnoticed, 
therefore the possible detection of carbapenemases will be overlooked.    
 
 
The MHT and AMC double disc synergy test have been reported to be used for the detection 
of carbapenemase production. In our study the MHT was used to determine the presence of 
various carbapenemases produced by the test isolates, evident by a clover-leaf indentation 
pattern (as shown in Fig, 7). It should also be stated that the isolates that produced 
carbapenemases, and in turn were positive for the MHT, should have been resistant to at least 
1 carbapenem agent. However, in this study the results obtained from the MHT showed that 
the clover-leaf indentation appeared for isolates that had diverse susceptibility patterns for the 
carbapenems based on the Kirby-Bauer susceptibility test. These results were similar to a 
study by Cury et al. (2012), where the MHT was only used for the detection of KPC 
carbapenemases among Enterobacteriaceae. In the latter study, 7 isolates showed positive 
MHT results but were negative for blaKPC. It was therefore postulated that these isolates 
harboured other types of carbapenemases, produced CTX-M or hyperproduced AmpC (Cury 
et al., 2012). This is in contrast to results observed in a study by Castanheira et al. (2011), 
where 11 of 15 NDM-1 producing isolates were negative and weakly positive for the MHT. 
All other carbapenemase producers showed positive results for the MHT. The MHT may 
therefore be problematic for the detection of the NDM-1 strains due to false-negative results. 
It is unreliable as a screening test for CPE and will not always be able to guide the 
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implementation of strict infection control measures. False-negative results will allow the CPE 
to go unnoticed and will allow the continuous spread of these organisms (Castanheira et al., 
2011).    
 
 
In other literature, the MHT was used for the specific detection of KPC and NDM β-
lactamases from pre-defined and characterised bacterial species (Cardile et al., 2014; Cury et 
al., 2012; Girlich et al., 2012; Ribeiro et al., 2014). This  might  be the reason for the high 
level of agreement with the molecular detection techniques (Cardile et al., 2014; Cury et al., 
2012; Girlich et al., 2012; Ribeiro et al., 2014). However, according to Thomson (2010), the 
MHT does not have the ability to differentiate between carbapenemase types and lacks 
sensitivity for the detection of MBLs. Furthermore, Ribeiro et al. (2014), explained that even 
though the MHT has >90% sensitivity, it was difficult to interpret and is prone to 
subjectivity. This was evident in the present study, since all test isolates that produced even 
the slightest indentation was taken as positive. However, according to Centers for Disease 
Control and Prevention (CDC), some isolates may produce a slight indentation but still lack 
carbapenemases. This was further proven by Ribeiro et al. (2014), in a study were the 
sensitivity and specificity of the MHT was performed for the detection of KPC. Positive 
results from the MHT was dependent on the enzyme activity, and the results showed that a 
larger and enhanced growth intensity (indentation) would occur with a stronger hydrolytic 
activity of the enzyme produced by the test organisms (Ribeiro et al., 2014). According to 
Thomson (2010), accurate results may have been observed if this test was performed 
according to the ‘true’ MHT method on MacConkey agar or carbapenem discs impregnated 
with zinc. False-positive results for the MHT normally arise due to high-level AmpC 
producers, and more specifically with an imipenem rather than the other carbapenems. In 
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screening tests it is uncertain which carbapenem disc will provide optimum results for the 
MHT. However, imipenem is the least specific agent but is the most sensitive for the 
detection of OXA enzymes (Thomson, 2010).   
 
 
A positive result from the AMC double disc synergy test has been reported to indicate the 
presence of the blaKPC. An augmented zone of inhibition around the carbapenem disc 
indicated resistance to the carbapenems as a result of carbapenemase activity (as shown in 
Fig. 8). However, similar to the results obtained from the MHT, isolates that were both 
resistant and susceptible to the carbapenems appeared positive for the AMC double disc 
synergy test. This test should assist in the elimination of isolates that produce AmpC β-
lactamases, since isolates with this enzyme usually confer resistance to clavulanic acid (β-
lactamase inhibitor) which is present in the AMC disc (Kocsis and Szabó, 2013). Although 
this test may not present false-positive results, the presence of AmpC interference may still 
occur due to the organism harbouring other ESBLs. This is because other ESBLs (apart from 




K. pneumoniae and E. cloacae isolates were selected for MICs based on their prevalence as 
well as the susceptibility patterns for all antibiotics tested. MICs are considered the ‘gold-
standard’ for determining the susceptibility of microorganisms to antimicrobial agents, and is 
therefore used to evaluate the performance of other susceptibility tests (Andrews, 2001). 
These methods provide definitive results if a borderline result is obtained from other 
phenotypic methods of testing (Andrews, 2001). 




When comparing the CLSI breakpoints to the EUCAST breakpoints it was evident that the 
CLSI breakpoints reported resistance at a lower level than the EUCAST breakpoints. The 
resistant CLSI breakpoints for the carbapenems were as follows: ≤8 mg/L for ertapenem, ≤16 
mg/L for imipenem and ≤16 mg/L for meropenem. There was no CLSI breakpoint for 
doripenem. The EUCAST resistant breakpoints for the carbapenems were as follows: ≥1 
mg/L for ertapenem, ≥4 mg/L for doripenem, and ≥8 mg/L for imipenem and meropenem. A 
total of 12 isolates were resistant to the carbapenems based on the EUCAST breakpoints. 
However, based on the CLSI breakpoints, it was observed that only one isolate, E. cloacae 
EC9 (≥8 mg/L for ertapenem from VITEK® 2) was resistant from all the K. pneumoniae and 
E. cloacae isolates tested. This implied that the difference in the breakpoints were significant. 
It was evident that if the CLSI guidelines were used, isolates that may have been resistant to 
the carbapenems would not have been identified.     
 
  
The E-test was performed for ertapenem, imipenem and doripenem (E-tests for meropenem 
were not performed due to the suppliers (Biomerieux, France) experiencing quality control 
problems and the batches produced being recalled. The new batches will only be available in 
2015). Only meropenem, imipenem and ertapenem MICs were performed based on the 
VITEK® 2 automated system, since doripenem is unavailable for this system. Among the K. 
pneumoniae isolates, only KP37 was resistant to all carbapenems based on the microbroth-
dilution and E-test methods, but was only resistant to ertapenem based on the VITEK® 2. 
The E-test and the VITEK® 2 produced the same MIC for ertapenem. However, the E-test 
showed greater resistance for ertapenem and doripenem since the MIC increased from 4 
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mg/L to 6 mg/L for both the antibiotics, in comparison to the microbroth-dilution method. 
The MICs for ertapenem for isolate KP5 differed when comparing the 3 methods. The MIC 
values for this isolate was 1 mg/L, 0.75 mg/L and 0.5 mg/L for the microbroth-dilution, E-
test and VITEK® 2, respectively. Only one other K. pneumoniae isolate (KP29) was resistant 
to ertapenem based on the VITEK® 2 results but was susceptible based on the microbroth-
dilution and E-test. In a study performed by Brink et al. (2013), the MICs for most OXA-48 
producing K. pneumoniae fell within the range of 16 to 32 mg/L for all 4 carbapenems which 
was slightly greater than that observed in the present study for KP37. However, isolate KP37 
produced much higher levels of resistance in comparison isolates KP5 and KP29, which was 
probably due to these organisms producing chromosomally encoded resistance mechanisms.  
 
 
The E. cloacae isolates appeared to show more resistance than K. pneumoniae, since a total 
of 11 isolates had resistant MIC values. The MICs of the E. cloacae isolates differed 
significantly when comparing the VITEK results to the microbroth-dilution and E-test results. 
The MIC for ertapenem for isolate EC5 was 1.5 mg/L and 1 mg/L based on the VITEK® 2 
and E-test, respectively. The MIC for ertapenem for isolate EC6 was 2 mg/L and 4 mg/L 
based on the VITEK and E-test, respectively. However, both these isolates were susceptible 
to ertapenem, with a similar MIC value of 0.5 mg/L, based on the microbroth-dilution test. 
Isolate EC9 was only resistant to ertapenem based on the microbroth-dilution and VITEK® 2 
but was intermediate based on the E-test results. The VITEK® results showed that isolate 
EC9 had a MIC value ≥8 mg/L for ertapenem, which was 6 mg/L and 7.25 mg/L greater than 
the microbroth-dilution and E-test, respectively. Several other E. cloacae isolates were 
resistant based on the VITEK® 2, but were susceptible based on the microbroth-dilution and 
E-test. However, from the VITEK® 2 AES it was assumed that all these resistant isolates 
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produced carbapenemases, which was not the case. The MIC results from this study were 
much lower than MIC values produced in a study by Sianou et al. (2012). In the latter study 
the microbroth-dilution was used to determine the MICs of isolates that harboured the VIM 
β-lactamase. The MICs for the carbapenemase positive K. pneumoniae were 16 mg/L, 16 
mg/L and 4 mg/L for imipenem, meropenem and ertapenem respectively; and 4 mg/L, 4 
mg/L, and 2 mg/L for these carbapenems for carbapenemase positive E. cloacae (Sianou et 
al., 2012).    
 
 
The E-test appeared to be more accurate for the lower dilutions since this went down to a 
MIC value of 0.008 mg/L. The majority of K. pneumoniae and E. cloacae isolates in this 
study were susceptible and fell within the range of 0.5 mg/L to 0.008 mg/L. In all 3 MIC 
methods used, it was evident that the isolates were more frequently resistant to ertapenem 
than to imipenem, meropenem or doripenem. The opposite result was obtained in a study by 
Viau et al. (2012), who found that the MICs for ertapenem are more sensitive to K. 
pneumoniae, however this antibiotic lacks specificity and therefore further testing is required. 
According to Brink et al. (2013b), the OXA-48-like producers in South Africa were non-
susceptible to ertapenem and had a MIC value of 2 mg/L. These isolates may confer only a 
slight increase in carbapenem MICs due to weak hydrolytic activity in the absence of related 
mechanisms (Brink et al., 2013b). 
 
 
In literature, Livermore et al. (2012), stated that the MIC values obtained from the E-tests 
frequently differed from the automated VITEK® 2 system. In a study by McGettigan et al. 
(2009), the VITEK® 2 was 65% and 48% sensitive to imipenem and meropenem, 
- 81 - 
 
respectively. This proved to be insensitive for the aforementioned antimicrobial agents, 
which was similar to the current study. Similarly, Brink et al. (2012a), showed that the 
automated system  had low sensitivity (74%) and specificity (38%) for the identification of 
carbapenemases. In the current study, the MICs from the VITEK® 2 were similar in 
comparison to the microbroth-dilution and E-tests for the K. pneumoniae isolates. Isolate 
KP37 was the only strain that had similar resistant results for all 3 MIC methods for 
ertapenem.     
 
 
The VITEK® 2 is an automated system that is used as an ESBL confirmatory test and is 
referred to as an expert system which should distinguish ESBLs from other β-lactamases 
(Thomson et al., 2007). According to Brink et al. (2012b), this system is normally used for 
routine diagnostic testing since it should provide interpretations that do not require further 
laboratory screening, which was evident in the current study. However in a study by 
Thomson et al. (2007), this was not the case since the VITEK® 2 system seemed to be more 
complicated as the mechanism of resistance needs to be identified prior to set-up. In addition, 
some isolates may not be detected accurately by the machine resulting in continuous looping 
and repetition of the test and results obtained are usually inconclusive (Thomson et al., 2007). 
According to the results from our study, it was evident that the VITEK® 2 interpretation of 
MICs is inaccurate in comparison to the other MIC tests used. This is because the AES 
compares the test isolates to its database. This database comprises of previously described 
reports that had various mechanisms of resistance for specific isolates with specific MICs. 
Therefore if the results from a test isolate differs from that found in the database, the AES 
will interpret the result as inconsistent, which was similar to the result for K. pneumoniae 
KP37 in this study.  
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The phenotypic tests in this study produced unreliable results, possibly due to the presence of 
other ESBLs. None of the phenotypic tests performed had the ability to determine if the 
isolates harboured a carbapenemase-type enzyme or had the ability to detect which type of 
carbapenemase was present. Therefore, molecular detection may be the only rapid and 
reliable means for the detection of carbapenemases. In this study, from the 94 K. pneumoniae 
and 41 E. cloacae isolates and of the six carbapenemases tested, only a K. pneumoniae strain 
(KP37) was a carbapenemase producing isolate, which harboured a blaOXA-48 enzyme. The 
strain was isolated from MacConkey agar and did not grow on either of the chromogenic 
plates. Similarly, in a study performed by Wilkinson et al. (2012), Brilliance™ CRE agar and 
ChromID® CARBA agar were unable to support the growth of OXA-48 producers.  
 
 
The KP37 was resistant to ertapenem, ciprofloxacin, naladixic acid, cefoxitin, cefotaxime, 
ceftazidime and chloramphenicol based on the Kirby-Bauer susceptibility test. According to 
Poirel et al., (2012b), isolates that produce the OXA-48 enzymes vary in terms of β-lactam 
resistance patterns: some isolates are susceptible to broad-spectrum cephalosporins and 
carbapenems, some are susceptible to broad-spectrum cephalosporins but are resistant to 
carbapenems, and others are resistant to broad-spectrum cephalosporins and carbapenems. 
The MHT results for EC37 were positive for all 4 carbapenems and negative for the AMC 
double disc synergy test, which was expected since the AMC inhibitor is presumably positive 
only for KPC production. The KP37 strain was also resistant to all carbapenems from the 
microbroth-dilution and E-tests which seemed reliable. However, according to Wilkinson et 
al. (2012) and Nordmann et al. (2012), the detection of these strains are difficult since they 
normally produce low carbapenem MICs and/ or are susceptible to cephalosporins when there 
is no coproduction of ESBL or AmpC enzymes. Furthermore, Poirel et al. (2012a) reported 
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that the production of carbapenemases should be suspected among Enterobacteriaceae that 
have MIC values of ≥ 0.5 mg/L for ertapenem, and ≥ 1 mg/L for imipenem or meropenem.  
 
 
The OXA-type enzymes are predominantly observed among Acinetobacter sp., and has only 
recently been described in K. pneumoniae and E. coli (Kocsis and Szabó, 2013). Recently in 
South Africa, 38 Enterobacteriaceae were screened, of which 25 were positive for 
carbapenemases. These CPE were most commonly detected in K. pneumoniae and E. 
cloacae. Among these CPE, 19 were NDM-1 producers: 3 were from a private hospital in 
KwaZulu-Natal, and 16 were from public hospitals in Gauteng. The β-lactamase OXA-48 
producers were also detected: 1 from a private hospital in Gauteng and 3 from public 
hospitals in Gauteng and Eastern Cape (NICD-NHLS, 2014).  
 
 
The search for CPEs that have reduced susceptibility to carbapenems is imperative due to the 
paucity of therapeutic options for the treatment of infections caused by such isolates (Poirel et 
al., 2012a). In addition, there appears to be inadequate knowledge of the spread of in vivo 
mutants with an enhanced level of resistance to carbapenems by means of other resistance 
mechanisms (Poirel et al., 2012a). Several K. pneumoniae and E. cloacae isolates in this 
study appear to be resistant to the carbapenems but were negative for carbapenemase 
production. These isolates could harbour other variants of carbapenemases that were not 
detected based on ESBL RT-PCR kits or may have developed alternate mechanisms of 
resistance such as the production of plasmid mediated AmpC enzymes, efflux pumps or 
outer-membrane proteins. In literature, isolates that overexpress the plasmid mediated AmpC 
enzymes confer resistance to extended-spectrum cephalosporins including cefotaxime, 
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ceftazidime, and ceftriaxone, which were similar resistance patterns observed in the non-
carbapenemase producers in our study. Several Gram-negative bacilli have the ability to 
produce chromosomally mediated AmpC which when hyperproduced, may lead to resistance 
against penicillin, aztreonam, and cephamycins (Thomson, 2010). Isolates that have 
chromosomes and plasmids that encode the AmpC enzyme, have the ability to hydrolyse 
broad-spectrum cephalosporins more efficiently (Kocsis and Szabó, 2013).  
 
 
The rapid detection of carbapenemases, more specifically KPC, NDM-1 and OXA-48 
enzymes as a result of the increased prevalence in South Africa, is crucial in order to 
introduce appropriate treatment, and implement suitable infection control measures (Coetzee 
and Brink, 2011). To our knowledge, the blaOXA-48 detected among neonates in this study was 
the first to be detected in KwaZulu-Natal. This is a cause for concern since OXA-48 is one of 
the most prevalent carbapenemases transmitted and appears to be increasing rapidly 
worldwide. The screening of colonised neonates is imperative for the identification of 
patients that may be a potential threat to others via horizontal gene transfer (Lowman et al., 
2014). In order to do so, there needs to be a significant microbial load, in combination with 
the mode of transmission (Lowman et al., 2014). It is possible that the primary reason for the 
transmission of CPE is due to contact between hospital personnel and neonates as a result of 
inappropriate hand hygiene practices. Therefore the implementation and adherence to basic 
infection control measures are necessary to reduce and eventually prevent the spread of 









Based on South African publications, it is evident that colonised patients that have not been 
screened for CPE, unknowingly allow for the transmission of these organisms. Therefore the 
recognition of these colonised patients is essential for the implementation of correct infection 
control measures in order to reduce the risk of transmission. Various risk factors associated 
with the dissemination of CPE in NICU need to be taken into account, this includes low birth 
weight, prematurity, duration of hospitalization, use of invasive devices and prolonged 
administration of antibiotics (Bonura et al., 2013).     
 
  
Controlling the transmission and reducing the impact of CPE in South Africa will require 
serious efforts in public and private healthcare sectors in order to move forward. This case 
differs from one in South Africa, where a patient inhabited with an OXA-48 producing K. 
pneumoniae isolate was colonised with this strain throughout hospitalisation. This 
encouraged the screening for genes among Enterobacteriaceae that were resistant to 
carbapenems. In 2013, 240 ertapenem-non-susceptible isolates were screened, 33 of which 
were positive for blaOXA-48 isolated from clinical cultures and rectal carriages (Govind et al., 
2013). Although the current study only revealed a single neonate colonised with an OXA-48 
carbapenemase, this showed that CPE are in fact in the nursery environment at King Edward 
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The microbroth-dilution test using EUCAST criteria appears to be the best test for MIC 
determination. However, more robust tests are required for the rapid detection of CPEs 
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APPENDIX A: BREC approval letter 
 
 




Table 1: The duration of specimen collection from 30 neonates at KEH VIII hospital 
Ward Laboratory number 
Observation 1 R1 to R15 
New Premature nursery R16 to R23 
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Table 2: The duration of specimen collection from 30 neonates at KEH VIII hospital 
 
 






























































































































R 1 X D                                         
R 2 X D                                         
R 3 X D                                         
R 4 X D                                         
R 5 X X D                                       
R 6 X X X X X X X X X X D                       
R 7 X D                                         
R 8 X D                                         
R 9 X X D                                       
R 10 X D                                         
R 11 X X D                                       
R 12 X X D                                       
R 13 X D                                         
R 14 X X X X X X D                               












R 16 X X X X X X X X X X X D                     
R 17 X X X X X X X X X X X X X X X X X D         
R 18 X X X X X X D                               
R 19 X X X X X X X X X X D                       
R 20 X X X X X X X X X X X X X X X X X X X X X D 
R 21 X X X X X X X X X X X X D                   
R 22 X -                                         












R 24 X X D                                       
R 25 X D                                         
R 26 X X D                                       
R 27 X X D                                       
R 28 X X X X X X X X X X D                       
R 29 X D                                         
R 30 X X X X X X X X X X X D                     




1. Preparation of media used in this study: 
 
1.1. MacConkey agar (CM0007) 
MacConkey agar powder 52 g 
Distilled water  1 L 
 
Prepared by adding 52 g of powder into 1 L of distilled water. This was mixed until powder 
was thoroughly dissolved and autoclaved at 121 °C for 15 min.   
 
 
1.2. Mueller-Hinton agar (CM0405)   
Mueller-Hinton powder 21 g 
Distilled water  1 L 
 
Prepared by adding 21 g of powder into 1 L of distilled water. This was mixed until powder 
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1.3. Mueller-Hinton broth (CM0337) 
Mueller-Hinton broth powder  38 g 
Distilled water   1 L 
 
Prepared by adding 38 g of powder into 1 L of distilled water. This was mixed until powder 
was thoroughly dissolved and autoclaved at 121 °C for 15 min.   
 
 
1.4. Blood agar 
Columbia Blood agar base powder 39 g 
Distilled water   1 L 
Horse blood     50 ml 
 
Thirty nine grams of Columbia Blood agar base (CM0331) powder was dissolved into 1 L of 
distilled water. This was mixed until powder was thoroughly dissolved and autoclaved at 121 
°C for 15 min. After autoclaving, agar was cooled down to 55 °C in a water bath. Only when 
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1.5. Storage media 
BHI (Brain Heart Infusion) broth 12 g 
Distilled water   400 ml 
Glycerol     100 ml 
Glass beads 
 
Twelve grams of BHI was dissolved into 400 ml of distilled water. Thereafter, 100 ml of 
glycerol was added and autoclaved at 121 °C for 15 min. Three quarter of the cryovials was 
filled with polysterene beads. Five hundred microlitres of the storage media was dispensed 





































ADH L-arginine Arginine Dihydrolase Yellow red/ orange
2
 
LDC L-lysine Lysine Decarboxylase Yellow red/ orange
2
 









H2S sodium thiosulfate H2S production colourless/ greyish 
black deposit/ 
thin line 
URE urea Urease Yellow red/ orange
2
 
TDA L-tryptohane Tryptophane Deaminase Yellow reddish brown 
IND 
L-tryptohane Indole production 
colourless/ pale 
green/ yellow pink 
VP 
sodium pyruvate 
acetoin production (Voges 











































(arabinose) blue/ blue-green yellow 
* Fermentation starts in the lower portion of the tubes, oxidation starts in the cupule 
1
Avery pale yellow is considered a positive reaction 
2
An orange colour after incubation for 35-48 h is considered negative 
3
Reading made in the cupule (aerobic) 
4
A slightly pink colour after 10 min is considered negative 
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ONGP + + + + _ + + _ 
ADH _ + _ _ _ + _ _ 
LDC + _ + + _ + + _ 
ODC _ + + _ + + + + 
CIT + + + _ _ + + _ 
H2S _ _ _ _ + _ _ _ 
URE + _ _ _ + _ _ + 
TDA _ _ _ _ + _ _ + 
IND _ _ _ + _ _ _ + 
VP + + + _ _ + + _ 
GEL _ _ _ _ + + + _ 
GLU + + + + + + + + 
MAN + + _ + _ + + _ 
INO + _ _ _ _ + + _ 
SOR + + _ _ _ + + _ 
RHA + + _ + _ + _ _ 
SAC + + _ _ _ + + _ 
MEL + + _ + _ + + _ 
AMY + + _ _ _ + + _ 
ARA + + _ + _ + _ _ 
 
  





1.1. Calculations of antibiotic stock solutions: 
Weight of powder  = [highest concentration (µg/ml)] x [volume (ml)]  
     (potency µg/mg)                                                   
          = powder weight (µg/ml)  
Note: increase by x10 concentration if non-toxic or by x100 concentration if toxic. 
 
Diluent required  = [weight of powder (µg/ml)] x [volume of diluent (ml)] 
 
Note: A 1:10 dilution was prepared from the antibiotic stock to bring the concentration back 

















1. DNA Extraction Solutions  
 
1.1. 10x TE Buffer  
Trizma base (Sigma-Aldrich, USA)    1.21g  
EDTA (Sigma-Aldrich, USA)            0.37g  
  
Weigh out the required amounts of reagent powders and dissolve the trizma base in 80ml of 
distilled water, pH to 8 using concentrated HCl (Merck).  Add the EDTA and dissolve. Check 
the final pH and adjust to a final volume of 100ml. Autoclave at 121°C for 15 minutes.  
  
Preparation of 1x TE Buffer:  
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1.2.Preparation of Mastermix 
 
Table 4a: RT-PCR reaction for KPC, NDM and OXA-48 and variants  
Mastermix components Quantity 
Probes Master  10.0 µl 
Lightmix Modular NDM-1 (ESBL) 0.5 µl 
Lightmix Modular OXA-48(ESBL) 0.5 µl 
Lightmix Modular KPC (ESBL) 0.5 µl 
Lightmix Modular PhHV internal control 0.5 µl 
PCR-grade water 3.0 µl 
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Table 4b: RT-PCR reaction for IMP, VIM and GES and variants  
Mastermix components Quantity 
Probes Master  10.0 µl 
Lightmix Modular IMP (ESBL) 0.5 µl 
Lightmix Modular VIM (ESBL) 0.5 µl 
Lightmix Modular GES (ESBL) 0.5 µl 
Lightmix Modular PhHV internal control 0.5 µl 
PCR-grade water 3.0 µl 
Total Mastermix volume 15.0 µl 
 
 
Table 4c: Components required in the final multiplex real-time PCR reaction 
Mastermix volume 15.0 µl 
Volume of DNA 5.0 µl 
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2. Cycle conditions for multiplex real-time PCR using the Light Cycler 480 II 










Denaturation 95 None 5 4.4 1 
 
Quantification 
95 None 15 4.4  
45 
 
60 None 30 2.2 
72 Single 2 4.4 
Cooling 40 None 30 2.2 1 
 
 
3. Remaining illustrations for multiplex real-time PCR: 
 
Fig. 1a: Real-time PCR results for blaKPC: test isolates 1 to 24. Blue amplification curve: NICDs in-house KPC 
positive control (K. pneumoniae ATCC BAA1705). Grey and Dark Blue amplification curve: KPC positive kit 
control (Roche, Switzerland). Flat lines: represent all isolates that were negative for blaKPC.  
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Fig. 1b: Real-time PCR results for blaKPC: test isolates 25 to 47. Blue amplification curve: KPC positive kit 
control (Roche, Switzerland). Flat lines: represent all isolates that were negative for blaKPC. 
 
Fig. 2a: Real-time PCR results for blaOXA-48 for 23 to 47: Green amplification curve: OXA-48 positive kit 
control. Red amplification curve: test isolate 46 which is negative (CP >40.00). Flat lines: represent all isolates 
that were negative for blaOXA-48.   
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Fig. 3a: Real-time PCR results for blaNDM-1: test isolates 1 to 24. Grey amplification curve: NICDs in-house 
KPC positive control (K. pneumoniae ATCC2146). Yellow and Red amplification curve: NDM-1 positive kit 
control (Roche, Switzerland). Flat lines: represent all isolates that were negative for blaNDM-1.. 
 
 
Fig. 3b: Real-time PCR results for blaNDM-1: Bright red amplification curves: NDM-1 positive kit control. Blue 
amplification curve: NICDs in-house blaNDM-1 K. pneumoniae ATCC2146 ).  Dark red amplification curve: 
environmental test isolate 43 (Bucket A). Flat lines: represent all isolates that were negative for blaNDM-1..   
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Fig. 4a: Real-time PCR results for blaVIM: test isolates 1 to 24. Dark blue amplification curve: NICDs in-house 
VIM positive control (Pseudomonas aeruginosa clinical strain). Yellow and Red amplification curve: VIM 
positive kit control (Roche, Switzerland). Flat lines: represent all isolates that were negative for blaVIM.   
 
Fig. 4b: Real-time PCR results for blaVIM: test isolates 25 to 47. Red amplification curve: VIM positive kit 
control (Roche, Switzerland). Flat lines: represent all isolates that were negative for blaVIM. 
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Fig. 5a: Real-time PCR results for blaIMP: test isolates 1 to 24. Light Blue amplification curve: NICDs in-house 
IMP positive control (E. coli NCTC 13476). Dark Blue and Grey amplification curve: IMP positive kit control 
(Roche, Switzerland). Flat lines: represent all isolates that were negative for blaIMP. 
 
 
Fig. 6a: Real-time PCR results for blaIMP: test isolates 25 to 47. Blue amplification curve: IMP positive kit 
control (Roche, Switzerland). Flat lines: represent all isolates that were negative for blaIMP. 
 
- 125 - 
 
Fig. 6b: Real-time PCR results for blaGES: test isolates 1 to 24. Orange amplification curve: NICDs in-house 
GES positive control (K. pneumoniae clinical strain). Red and Green amplification curve: GES positive kit 
control (Roche, Switzerland). Flat lines: represent all isolates that were negative for blaGES. 
 
Fig. 7a: Real-time PCR results for blaGES: test isolates 25 to 47. Green amplification curve: IMP positive kit 
control (Roche, Switzerland). Flat lines: represent all isolates that were negative for blaGES.. 
 
 
 
 
 
 
